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ABSTRACT OF DISSERTATION
THERAPEUTIC DRUG MONITORING OF BETA-LACTAM ANTIBIOTICS IN
CRITICALLY ILL PATIENTS WITH SEPSIS
Sepsis is a devastating diagnosis affecting over 750,000 patients a year, accounting for
approximately 10% of all hospital admissions, costs more than $50,000 per patient, and
exceeds $17 billion annual spending. The mortality rate for sepsis remains unacceptably
high: one out of every three patients diagnosed with sepsis dies. Sepsis physiology induces
physiologic changes to drug pharmacokinetic (PK) parameters that alter the ability to
achieve the goal pharmacodynamic (PD) target for beta-lactams of >4-fold unbound
concentration above the minimum inhibitory concentration for 100% of the dosing interval
(100% fT >4x MIC). Sepsis treatment such as volume resuscitation and vasopressor agents
increase cardiac output and circulating blood flow, resulting in increased glomerular
filtration and enhanced elimination of antibiotics. The PK alterations observed in critically
ill septic patients are strongly associated with sub-optimal beta-lactam concentrations. Suboptimal beta-lactam dosing has resulted in higher rates of therapeutic failure and increased
mortality in critically ill patients with sepsis. In addition to the risk of under-exposure,
growing data suggest certain beta-lactam combinations are associated with increased
nephrotoxicity. Therapeutic drug monitoring of beta-lactam antibiotics is a strategy to
improve the outcomes of critically ill septic patients by maximizing efficacy and
minimizing toxicity.
KEYWORDS: Sepsis, Therapeutic Drug Monitoring, Beta-lactam, Antibiotics,
Personalized medicine
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CHAPTER 1. BACKGROUND: PHARMACOKINETIC ALTERATIONS AND
ANTIBIOTIC DOSING IN SEPSIS
1.1.1

Sepsis overview and role of
antibiotics

Sepsis is a medical emergency associated with 30% mortality rate and should be
considered a public health crisis. Sepsis is a devastating diagnosis affecting over 750,000
patients a year, accounting for approximately 10% of all hospital admissions, costs more
than $50,000 per patient, and exceeds $17 billion annual spending. (Lagu, Rothberg et al.
2012, Angus and van der Poll 2013) In 2017, 48.9 million cases of sepsis were recorded
globally, causing 11 million deaths. (Rudd, Johnson et al. 2020)
Sepsis is characterized by a dysregulated host response to infection. There are
various phenotypes described in the host sepsis response, ranging from hyper-immune to
hypo-immune, which makes it challenging for clinicians to predict which patients will
progress to the most severe form (sepsis with organ failure, or shock), and who will not.
(Angus and van der Poll 2013) Despite advances in care over the last 2 decades, one out of
every three patients diagnosed with sepsis dies. The mainstay for sepsis treatment resides
in supportive care of injured systems, and supporting damaged organs. The organ failure
associated with sepsis often affects the respiratory and cardiovascular systems, but also the
kidneys. Multi-organ failure in sepsis is associated with the highest risk of death, which
increases with each failed organ. (Lagu, Rothberg et al. 2012, Angus and van der Poll 2013,
Rudd, Johnson et al. 2020) As there is not a drug available to treat sepsis directly, the
treatment of sepsis focuses largely on supportive care, and treating the underlying
infection. (Fink and Warren 2014) Thus, antibiotics are the only drug available to treat the
underlying cause of sepsis. Therefore, appropriate antibiotic selection (agent, dose, route)
1

is of utmost importance when treating a septic patient. International sepsis guidelines
recommend empiric anti-pseudomonas antibiotics for sepsis, such as cefepime,
meropenem, aztreonam or piperacillin-tazobactam. (Rhodes, Evans et al. 2017)
As such, one of the most important predictors of mortality in sepsis is early
administration of the above-mentioned appropriate antibiotics. (Liu, Fielding-Singh et al.
2017, Rhodes, Evans et al. 2017) Kumar and colleagues evaluated the timing of antibiotic
administration in septic shock patients and found that a delay in antibiotic administration
beyond the first hour of hypotension was associated with an increased risk in hospital
mortality (odds ratio 1.67; 95% confidence interval, 1.12–2.48). (Kumar, Roberts et al.
2006) A confirmatory study from a large retrospective database of 35,000 inpatient cases
of sepsis or septic shock found a 9% increased risk of death for each hour delay in
administration; adjusted OR 1.09 (95% confidence interval [CI], 1.05-1.13)]. (Liu,
Fielding-Singh et al. 2017) This study highlights the importance of early appropriate
antibiotics across the spectrum of the disease severity, with signals of improved outcomes
in patients with sepsis and septic shock. As the research evaluating impact of timing of
antibiotic administration is mounting, an important theme is also emerging: the one-sizefits all dosing strategy of beta-lactam antibiotics is inadequate for critically ill patients.
(Boucher, Wood et al. 2006, Roberts, Paul et al. 2014, Tsai, Lipman et al. 2015, Ehmann,
Zoller et al. 2017, Rhodes, Evans et al. 2017)
1.1.2 Pharmacokinetic and
Pharmacodynamics in critical
illness Pharmacokinetic
alterations
There are many changes which occur in critically injured sepsis patients that impact
the way drugs are distributed into the body, metabolized, and eventually eliminated. This
2

is the science of pharmacokinetics, and the full understanding of these changes is
paramount for optimizing antimicrobial therapy in sepsis. The changes specifically
observed to be important for beta-lactam antibiotics are: 1) increased volume of
distribution (Vd), which will decrease the initial concentration measured immediately
following the dose, and 2) increased glomerular filtration, which will increase drug
elimination. Changing either of these properties will alter the total body clearance of the
drug. Plasma protein binding is also altered in sepsis, which can be significantly
challenging with highly protein bound drugs, however the beta-lactam antibiotics in
question (cefepime, meropenem and piperacillin-tazobactam) are not highly protein bound.
The significance of alterations in plasma protein biding for these specific antibiotics has
not been established. In summary, the pharmacokinetic alterations seen in critically ill
patients with sepsis significantly alter the predicted concentrations, which have been
established in young healthy volunteers following a standard dose. (Boucher, Wood et al.
2006, Tsai, Lipman et al. 2015)
The observed volume of distribution is often profoundly larger in critically ill
patients, as compared to healthy controls. Intravascular volume expansion, which is a
mainstay of the treatment of shock is recommended in international guidelines. Most septic
patients will receive at least 30ml/kg as an initial crystalloid volume dose, and many
patients receive much more. (Rhodes, Evans et al. 2017) Net increase interstitial fluid
accumulation occurs due to this routine practice of volume resuscitation, and is enhanced
by the underlying pathology of the disease state. Endothelial injury from sepsis and
increased capillary permeability facilitate third spacing of intravascular fluid into nonvascular compartments, such as the tissues and lungs. The emptying of the vascular space
precipitates shock, and the need for intravascular volume expansion. These mechanisms
3

independently and collectively increase the apparent Vd of hydrophilic drugs, such as:
aminoglycosides, beta-lactam antibiotics, vancomycin, daptomycin. Simply stated, when
the intravascular fluid moves into these extra-vascular spaces (the cell, muscle, lungs,
skin)- the hydrophilic beta-lactam antibiotics follow. The large increase in the Vd has been
observed in many patient phenotypes of sepsis, including those in the early stages of sepsis,
or hyper-dynamic sepsis, and those receiving extra corporeal renal dialysis. In a study of
surgical prophylaxis patients, gentamicin pharmacokinetic parameters were monitored.
The septic patients vs. non-septic patients had an increased Vd from 0.29 L/kg to 0.48 L/kg.
(Tang, Tang et al. 1999) In a different population of critically ill septic patients in acute
renal failure requiring continuous renal replacement therapy (CRRT), the daptomycin
pharmacokinetic parameters were measured. The typical range of Vd of daptomycin, as
measured in healthy controls is 0.08-0.15 L/kg, which was increased to 0.23 L/kg in the
critically ill patients in this study. (Khadzhynov, Slowinski et al. 2011, Vilay, Grio et al.
2011)
Another study in 80 patients with septic shock, acute renal failure (27%), and
mechanical ventilation (71%) with a positive fluid balance at 24h (2.5L) measured betalactam serum concentrations. The measured volume of distributions of the beta-lactams in
this study were approximately double that of healthy volunteers published in package
inserts. Twenty-seven patients receiving piperacillin-tazobactam were observed to have a
mean (range) Vd of 0.38L/kg (0.29-0.43); compared to healthy volunteers a Vd of 0.2L/kg.
Sixteen patients receiving meropenem were observed to have a Vd of 0.43L/kg (0.31-0.77),
as compared to 0.28L/kg in healthy volunteers. Cefepime was given to 19 patients, who
displayed a mean (range) Vd of 0.36L/kg (0.33-0.44); which was substantially higher when
compared to healthy volunteers (0.26L/kg). (Taccone, Laterre et al. 2010) These studies
4

highlight the important differences observed when pharmacokinetic parameters are directly
measured in critically ill patients, as compared to healthy volunteers, or non-critically ill
comparison groups. Based on the relationship between Vd and peak serum concentrations,
one would need to double the dose in order to overcome the doubling of the Vd, in order
to achieve the optimal post-infusion concentrations, in these patients-. However, this is not
done routinely in clinical practice.
Another example of the variation of PK observed in critically ill patients is in a
study by Lheureux et al. (Lheureux, Trepo et al. 2016) The aim of this study was to observe
the impact of cirrhosis on pharmacokinetic measurements patients with sepsis. This study
compared the pharmacokinetic profiles of septic critically ill patients with and without
cirrhosis. Thirty-eight cirrhotic patients were matched to 38 non-cirrhotic pairs. All patients
received 2 measured samples of their respective antibiotic (meropenem and piperacillintazobactam). Cirrhosis was defined as a Child-Pugh class B or C. Patients were matched
on antibiotic (dose and type), 24- hour CrCl, CRRT intensity (for CRRT patients), SOFA
score and total body weight. Each drug was compared to the PK/PD goal of 50%T> 48xMIC piperacillin and 40% meropenem. The EUCAST MIC thresholds for P. aeruginosa
were ≤ 8 mg/L for piperacillin and ≤2 mg/L for meropenem. (Kahlmeter, Brown et al.
2006) Notable differences in pharmacokinetic profiles for the 2 drugs were observed. The
cirrhotic patients had a lower meropenem Vd (0.43L/kg [0.37–0.80] vs 0.77 L/kg [0.47–
1.12] 0.05) and a lower piperacillin CL, (24ml/min [16–41] vs. 39ml/min [28–62] p=0.009)
than their matched controls. The cirrhotic patients were more likely to have excessive betalactam levels, and experienced more neurologic side effects. The expected
pharmacokinetic alterations in cirrhosis (impact of impaired liver clearance, and reduced
protein binding) is evident in this study. Non-renal clearance and protein binding is
5

considered negligible for most beta-lactam antibiotics, however the impact on overall
pharmacokinetic profiles was significant in this study.
A systematic review of 57 studies summarized the impact of critical illness on
pharmacokinetic parameters of beta-lactam antibiotics. This study measured the Vd,
clearance, and tissue penetration of the beta-lactam antibiotics. (Goncalves-Pereira and
Povoa 2011) The clearance of meropenem ranged from (4.7L/hr to 15.4L/hr) in the
reviewed studies. Meropenem clearance closely correlated with CrCl in these patients,
however the variability across patients and within the same patient, reached up to 20%.
Tissue penetration was measured by microdialysis in several of the studies reviewed.
Measuring tissue penetration provides insight into how much drug is being delivered into
the site of infection. This concept has long been controversial, as assumptions are made
about the relationship between the concentration of the antibiotic in the serum to the site
of infection. Patients who are in shock, and on vasoactive agents to raise blood pressure
have reduced peripheral circulation, and possibly reduced delivery of the antibiotic to the
site of infection. For meropenem, the mean tissue: plasma ratio on day 1 of therapy was
0.44 for subcutaneous fat, and 0.74 in the peritoneum. The cumulative fraction of response
was calculated for each antibiotic across all studies reviewed. This is the numeric product
of multiplication of the percent target attainment for each MIC x the MIC distribution. This
allows the viewer to understand how the meropenem dosing regimen performs against a
variety of MICs encountered in the dataset. The cumulative fraction of response for
meropenem was 100% against Enterobacteriaceae and 40.6% for Pseudomonas during
intermittent bolus dosing. This increased to 100% for Pseudomonas when the dosing
strategy was changed to continuous infusion. The directly calculated Vd was often much
larger than expected from studies in healthy volunteers. For many beta-lactam antibiotics,
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(meropenem, cefpirome, cefepime, piperacillin) the Vd determined from heathy volunteers
fell outside of the range of measured volumes in this study. Piperacillin pharmacokinetic
measurements were also widely variable from established normal ranges in healthy
volunteers. Piperacillin clearance closely correlated to CrCl, yet many patients did not
reach target attainment (<15%). Microdialysis assessment of tissue penetration was done,
and revealed that the ratio of tissue: plasma was 0.1, correlating to 33% of the penetration
seen in healthy adults. The cumulative fraction of response of piperacillin with a 30-minute
infusion was found to be 53.4%, which increased to 92.3% with continuous infusion
dosing. Cefepime demonstrated a nearly doubling of the expected Vd in the reviewed
studies. At risk populations for altered cefepime pharmacokinetics included severe sepsis,
septic shock, elderly with sepsis, burn patients and those diagnosed with nosocomial
pneumonia. Cefepime clearance was found to correlate closely to CrCl (0.58- 0.77) in the
reviewed studies. The cefepime cumulative fraction of response of a 2gram twice daily
dose for Escherichia coli and Klebsiella pneumoniae was 78.9%, and for Pseudomonas
aeruginosa 53.6%. However, when increasing the dose to 2 grams three times daily the
cumulative fraction of response increased to 84.9%; a 4gm/day continuous infusion
increased to 91.7%, and 6 g/day increased to 94.8%. The cumulative fraction of response
for Acinetobacter baumanii with the maximum labeled dose in continuous infusion of 6
g/day, was only 75%. Microdialysis evaluation was done for cefepime in burned tissue and
found to be widely variable ranging from 0.4 to 5.1. Sample concentrations from bronchial
fluid in pneumonia patients were undetectable following an 89mg/kg/dose, however in a
different study, concentrations were measured and increased with use of continuous
infusion dosing strategy. Figure 1.1 below represent the various Vd observed in the studies,
as compared to known values from healthy volunteers.
7

Figure 1.1 Volume of distribution of study patients vs. healthy volunteers

In addition to the changes expected in volume of distribution and tissue
penetration, clearance of medications is often altered in critical illness. Traditional
glomerular filtration rate (GFR) equations that estimate a creatinine clearance based on
serum creatinine can be inaccurate in critically ill patients. (Baptista, Neves et al. 2014) A
prospective study done in 54 ICU patients (50% medical, 30% trauma) with a normal serum
creatinine was done to compare the accuracy of 3 serum creatinine GFR equations as
compared to the gold standard, an 8-hr urine creatinine collection test. The three methods
tested were the Modified Diet in Renal disease, Cockroft-Gault, and the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI). Data from 644 urine collection samples
were matched to their respective equations. The three equations had an overall correlation
coefficient of R = 0.2, suggesting poor agreement. In looking at sub-groups of patients with
8

various cut-off thresholds, the equations increasingly underestimated the GFR in patients
measuring >120ml/min, and overestimated the GFR when CrCl was <120ml/min. (Figure
1.2) The correlation coefficient remains low (R<0.3) at the various cut-off points of GFR
range.
Figure 1.2 Comparison of GFR equations to 8-hour urine creatinine at various thresholds
of GFR

Serum creatinine based GFR equations were not developed, and have not been
validated in critically injured patients. (Cockcroft and Gault 1976) The application of these
equations to the ICU patient population deserves further study, and should be scrutinized
when dosing medications. Determining medication dosing regimens based on flawed data
can result in over or under dosing of key therapeutics. In the previous study, 55% of the
patients exhibited augmented renal clearance (ARC). (Baptista, Neves et al. 2014) ARC is
defined as a GFR of ≥130 ml/min. The hallmark of ARC is enhanced glomerular filtration,
from which several factors and characteristics have been implicated in the causative
9

pathway, including increased renal blood flow, increased tubular anion secretion, renal
tubular absorption, and heightened non-renal elimination. (Udy, Jarrett et al. 2014)
In septic patients, volume resuscitation and vasopressor agents to restore
hypotension are the mainstay of initial hemodynamic management. Both interventions
increase cardiac output and circulating blood flow, resulting in increased glomerular
filtration and enhanced elimination of solute filtered through the kidney, leading to ARC.
(Sime, Udy et al. 2015) Figure 1.3 highlights the intricate pathophysiology and additive
effect of sepsis treatments on the risk of ARC.
Figure 1.3 Pathophysiology of augmented renal clearance

Although, only recently described in the medical literature, ARC has been
identified in several critical care disease states. Patients who are younger in age, male, low
serum creatinine at baseline, and a diagnosis of: sepsis, traumatic brain injury,
subarachnoid hemorrhage, burn, or neutropenic fever are at highest risk of ARC. A risk
stratification tool was developed, called the Augmented Renal Clearance in Trauma
10

Intensive Care scoring system (ARCTIC) score, to assist clinicians in the diagnosis of ARC
for trauma patients. (Barletta, Mangram et al. 2017) In this landmark study from 2017, a
retrospective evaluation of trauma patients determined predictors of ARC from weighted
logistic regression and ROC analysis. Three independent variables emerged as key
predictors for ARC in this population: age, serum creatinine, and gender. The weighted
ARCTIC score is found in Table 1.1 and can assist clinicians in proactively identifying
patients at high risk of ARC, and for whom may need more aggressive dosing regimens of
renally eliminated medications. An ARCTIC score of 6 or higher had a sensitivity of 0.843,
specificity of 0.682, positive predictive value of 0.842, and negative predictive value of
0.682, with an overall accuracy of 79%.
Table 1.1 ARCTIC Score

Variable

Points

Scr <0.7 mg/dl

3

Male sex

2

Age < 56 y

4

Age 56-75 y

3

ARC is difficult to predict and the effects on antimicrobial concentrations are
challenging to measure without therapeutic drug monitoring. A prospective observational
study done in Switzerland aimed to describe the prevalence of ARC, and describe any
association between ARC, beta-lactam concentrations, and clinical outcomes of patients
receiving beta-lactam antibiotics for sepsis. (Huttner, Von Dach et al. 2015) 100 Swiss
patients diagnosed with sepsis, and exhibiting a CrCl ≥60 mL/min were enrolled. Patients
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received beta-lactam TDM twice, once on days 1-3 and once again on day 5; 64/100 (64%)
of patients exhibited ARC diagnosed as a CrCl ≥130ml/min as calculated by the CockcroftGault creatinine clearance equation. (Cockcroft and Gault 1976) The beta-lactams
measured in this study were imipenem 500mg q6h, meropenem, 2gm q8h, piperacillin 4.5g
q8h, and cefepime 2gm q12g. The PK target for this study was T>100% 1x MIC, based on
EUCAST breakpoints. (Kahlmeter, Brown et al. 2006) Imipenem was the most commonly
encountered beta-lactam (54%), followed by piperacillin (33%), meropenem (11%) and
cefepime (2%). Sixty-four patients exhibited ARC, with a median (IQR) CrCl 166 ml/min
(145–200). ARC patients were younger, lower APACHE II scores and more likely to be
admitted for trauma and neurological illness than non-ARC patients. In this cohort, ARC
persisted at the 14-day point in 41/65 (76%) patients. Of all the trough concentrations
drawn in this study, 20% were undetectable, and 71% were sub-therapeutic.
A prospective observational study done in 79 patients with augmented renal
clearance, sepsis, shock (50%) and respiratory failure (20%) evaluated beta-lactam
concentrations in patients receiving a continuous infusion. (Carrie, Petit et al. 2018) The
beta-lactam doses were piperacillin 16gm or cefepime/ceftazidime/meropenem 6gm; all
regimens were infused over 24 hours. Blood samples were collected at 24, 48 and 72 hours.
ARC was diagnosed with a measured 24-h urine creatinine clearance within the first 72h
of therapy. The primary study outcome was sub exposure, defined as a serum concentration
< MIC of the bacteria, if the bacteria was not isolated, EUCAST breakpoints were used.
(Kahlmeter, Brown et al. 2006) (EUCAST) An a priori subgroup was also analyzed,
assessing the more aggressive PK/PD target of <4xMIC. All patients achieved a
concentration above the MIC, however 20% (16/79) of patients had sub-optimal betalactam levels (<4x MIC), which was statistically significantly associated with CrCl (150
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ml/min ± 66 vs 235 ± 58 ml/min, 246 ml/min p < 0.0001). The sub-optimal serum
concentrations were associated with higher rates of therapeutic failure 16% (13/79), and
development of resistant organisms 15% (2/13). (Carrie, Petit et al. 2018)
A sub-study by the same investigators sought to evaluate the impact of ARC on
differing doses of piperacillin and the ability to achieve PK/PD target attainment in various
scenarios of MIC breakpoints. (Carrie, Legeron et al. 2018) Monte Carlo simulation
(n=5000) was done on 3 dosing regimens 12gm/day, 16gm/day, and 20gm/day. For the
MIC of 16 (EUCAST breakpoint for Pseudomonas), the rate of underexposure was 19%
(11/59), which associated with a higher CrCl in the underexposed: (219 ml/min ± 31 vs
131 ml/min ± 50, p= 0.0001). Underexposure was not statistically significantly associated
with therapeutic failure (27.3% vs. 12.5%, p=0.22). A cut off of 170 ml/min predicted
underexposure with a sensitivity of 1 (95% CI: 0.79–1), and specificity of 0.69 (95% CI:
0.61–0.76). Other variables, including weight, and BMI had no association with
underexposure in this cohort. For patients with ARC and a CrCl of 170 ml/min, a daily
dose of 20gm of piperacillin is needed to achieve adequate serum concentrations. This
suggestion is above the currently labeled maximum dose of piperacillin, which is 16 gm a
day.
In summary, the myriad of pharmacokinetic alterations in critical illness predispose
patients receiving beta-lactams to under-exposure. These changes are not readily
measurable; thus, any preemptive dosing adjustment would be considered a bit like
shooting in the dark.
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1.1.3

Target attainment

There is a known relationship between beta-lactam concentration and bactericidal
activity. Beta lactam antibiotics exhibit time dependent killing. This simply means,
optimizing the time the serum concentration is a threshold above the minimum inhibitory
concentration (MIC) of the organism will optimize bactericidal effects and microbiologic
outcomes.

(Figure

1.4)

This,

time

above

the

MIC

(T>MIC),

is

the

pharmacokinetic/pharmacodynamic (PK/PD) goal for beta-lactam antibiotics
Figure 1.4 Concentration time curve representation of optimal beta-lactam PK/PD target.

The MIC of an organism is the concentration at which, visible growth is inhibited
on a microbiology plate. This threshold is determined for each antibiotic/ bacterium pair.
The MIC represents the minimum serum concentration that must be achieve with an
14

antibiotic, in order to kill the bacteria. With increasing MIC levels, the effectiveness of the
antibiotic is diminished. (Lodise, Lomaestro et al. 2006). Several limitations to the MIC
thresholds exist. This is considered a snapshot in time, which does not reflect bacterial
killing over the course of the entire dosing interval. It also does not provide information on
the impact of higher doses on bacterial killing. Finally, the MIC does not take into
consideration regrowth and killing of the organism, only the total net effect. Thus, while
MIC remains the gold standard for assessing antibiotic activity, there are several caveats
which must be taken into consideration when optimizing antibiotic dosing, and measuring
microbiologic cure. (Lodise, Lomaestro et al. 2006) However, ultimately, the MIC is still
the gold standard for assessing antibiotic susceptibility, and predicting therapeutic success.
The traditional PK/PD goal for beta-lactam antibiotics is based on the class of drug.
To optimize the bactericidal killing of cephalosporins, the concentration should be above
the MIC for 60-70% of the dosing interval; for penicillins 50%, and for carbapenems 40%.
(Lodise, Lomaestro et al. 2006) These thresholds are considered the bare minimum targets.
In recent years, a more aggressive target has been proposed for beta-lactams. The goal
TDM target for beta-lactams of >4-fold unbound concentration above the minimum
inhibitory concentration for 100% of the dosing interval (100% fT >4x MIC) has been
suggested as the optimal target for beta-lactams in critically ill patients. (Roberts, Paul et
al. 2014, Abdul-Aziz, Lipman et al. 2015) Achieving this TDM threshold has been
associated with improved bacterial killing, reduced emergence of resistant isolates,
increased microbiologic cure and improved clinical outcomes in critically ill patients.
(Olofsson, Geli et al. 2005, Abdul-Aziz, Lipman et al. 2015, Abdul-Aziz, Lipman et al.
2017) (McKinnon, Paladino et al. 2008) Beta-lactam serum drug monitoring is the only
way to monitor attainment of this TDM goal in critically ill patients with sepsis. (Boucher,
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Wood et al. 2006) Sepsis, and the treatment of sepsis, induce pharmacokinetic changes to
beta-lactam antibiotics, reducing the likelihood of achieving the TDM goal of (100% fT
>4x MIC).
Not achieving the goal PK/PD goal for beta-lactam dosing in critically ill patients
is associated with adverse patient outcomes. Inadequate beta-lactam levels in the early
stages of sepsis have been associated with increased mortality in gram-negative bacterial
infection. (Seyler, Cotton et al. 2011, Aitken, Altshuler et al. 2015, Carrie, Bentejac et al.
2018) Surviving Sepsis international guidelines recommends TDM-based optimization of
all antimicrobials in sepsis, including beta-lactam antibiotics, (Rhodes, Evans et al. 2017)
yet for various reasons, this recommendation is not implemented in every health system,
including the University of Kentucky Medical Center. (Wong, Brinkman et al. 2014)
Kaska and et al performed a pharmacokinetic study in 18 critically ill patients
admitted to a surgical ICU. (Kaska, Havel et al. 2018) The aims of this study were to
identify patient characteristics associated with reduced target attainment. Meropenem
dosed at 2 gm q8h over 3 hours, and piperacillin-tazobactam 4.5 gm q8h over 3 hours were
given to patient’s subject to TDM. The PK/PD goal of 100%fT>MIC was selected for this
model. The free concentration was determined from the total plasma concentration,
assuming the protein binding of piperacillin-tazobactam to be 22%, and assuming
negligible meropenem protein binding. Of the 18 patients, eight displayed augmented renal
clearance (44%) in this mixed trauma/surgical and septic population. TDM was performed
between days 2-3 of therapy pending the patient’s operation and procedures schedule. For
meropenem, all patients (8/8) obtained 100%fT > 2 mg/L; 12.5% (1/8) reached the
threshold of 100%fT>4-8 MIC, and 25% (2/8) who achieved the 100%fT>8 MIC. Overall,
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for meropenem, only 12.5% reached the optimal target for critically ill patients. In the
patients who received piperacillin-tazobactam, the goal 100%fT>16 mg/L was attained in
2/10 patients (20%). Seven patients with sub-therapeutic concentrations displayed ARC.
In a mixed-liner model, the ability for piperacillin-tazobactam to reach the PK/PD goal was
inversely related to cumulative fluid balance [β 1.2; (95% CI 0.55, 1.97) p=0.002].
Cumulative fluid balance was also positively associated with an increased Vd [β 0.02;
(95% CI 0.00, 0.03) p=0.021]. Similar trends were seen with meropenem, yet no estimate
reached statistical significance. This study has important limitations, the use of calculated
free concentrations using population pharmacokinetic extrapolation is considered
controversial, bearing in mind the wide variation seen in critically ill patients. This study
used the European committee for antibiotic testing (EUCAST) breakpoints for
Pseudomonas spp., a system not used in the United States, of which breakpoints can differ,
however not for Pseudomonas currently. (Kahlmeter, Brown et al. 2006) All 18 patients
did well clinically in this study, highlighting the need for larger clinical trials with more
robust patient data. Doses were not adjusted in this study, therefore the impact of TDM
optimization based on serum concentrations is unknown. There were no reports of toxicity
in this trial.
When septic patients go into renal failure requiring continuous renal replacement
therapy (CRRT), beta-lactam target-attainment and dosing is challenging, and standard
doses are often associated with sub-therapeutic concentrations. (Seyler, Cotton et al. 2011)
In a 53-patient study of septic patients with shock (23%) and mechanical ventilation (73%),
who were receiving CRRT at standard guideline doses of 22ml/kg/hr had serum
concentrations measured. The goal PK/PD parameter in this study was 4-5x>MIC for 40%
of the dosing interval. In patients receiving meropenem 1gm every 12, 81% of patients
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reached this threshold, zero cefepime (2gm q12h) patients reached the threshold, and only
71% of patients receiving piperacillin-tazobactam reached the goal at a dose of 4.5gm q6h.
Meropenem was also associated with significant accumulation at 48 hours. (Seyler, Cotton
et al. 2011). In another study conducted by Beumier et al, septic patients on CRRT (1634ml/kg/hr) who were mechanically ventilated (72%) and had mean admission APACHE
score of 21 received therapeutic drug monitoring of their beta-lactam antibiotic. (Beumier,
Casu et al. 2014) The PK/PD goal in this study was 4-5x MIC (≥40% meropenem ≥70%
cefepime and ≥50% piperacillin). Target attainment was defined as being able to achieve
this PK/PD goal for 90% of the time. Of the whole cohort, 92% of patients met their
respective target attainment. When TDM was performed early, 51% of patients exceeded
target attainment, and 58% exceeded target attainment when TDM was performed again at
48h. (Beumier, Casu et al. 2014) Target attainment is challenging to reach in critically ill
patients with sepsis, requiring CRRT, without therapeutic drug monitoring.

1.1.4 Antibiotic Dosing Controversies in Sepsis: Beta-lactam Toxicities
Considering the mounting data supporting under-dosing of beta-lactam antibiotics,
one may conclude empiric or preemptive dose increases should circumvent this issue.
However, toxicities have been reported with beta-lactams, many of which may exhibit a
concentration dependent effect.
Certain beta-lactam combinations are increasingly associated with increased risk of
acute kidney injury in sepsis. It is unknown at this time, if excessive piperacillin levels
contribute to this phenomenon. An abundance of observational data support the additive
toxicity of piperacillin/ vancomycin combinations over cephalosporin/ vancomycin
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combinations. A recent meta-analysis evaluated 24,799 patients concluding the odds of
developing acute kidney injury was 340% higher with vancomycin and piperacillin
combinations, over other beta-lactams, with a number needed to harm of 11 patients [Odds
ratio, 3.40; 95% CI, 2.57–4.50]. (Luther, Timbrook et al. 2018) The clinical impact and
nephrotoxicity risk associated with piperacillin and vancomycin combinations has
extensively evaluated. (Rutter, Burgess et al. 2017, Rutter and Burgess 2017, Rutter, Cox
et al. 2017) One recent study found a 218% increased risk of nephrotoxicity with
vancomycin and piperacillin over cefepime [OR 2.18;(95% CI, 1.64 to 2.94]. (Rutter, Cox
et al. 2017) As piperacillin is the workhorse beta-lactam in many institutions based on
bacteria susceptibility profiles, this growing body of literature is concerning for
practitioners. There is a need to identify the mechanism of this interaction, and piperacillin
therapeutic drug monitoring is the first step to solving this problem.
Many septic patients are at risk for under-dosing of beta-lactams; however, some
patients may be at risk of over-dosing, possibly increasing the risk of acute kidney injury.
TDM and personalization of dosing is the most precise way to select a dose for septic
patients, maximizing efficacy, while minimizing toxicity. Acute kidney injury in sepsis
doubles mortality and morbidity and can be prevented or attenuated with proper
monitoring. (Chertow, Burdick et al. 2005) Acute kidney injury in hospitalized patients
has been associated with significant increases in mortality, length of stay, and health care
costs. (Chertow, Burdick et al. 2005) There is a need to identify acute kidney injury early
in the patient course to prevent further damage and post- acute kidney injury
complications.
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Biomarkers of tubular damage or dysfunction may be valuable in assessing and
monitoring for clinical (and subclinical) acute kidney injury. Animal data suggests that
antibiotic exposure is associated with increased levels of kidney injury molecule-1 (KIM1) and neutrophil gelatinase-associated lipocalin (NGAL). (Luo, Chen et al. 2014, Rhodes,
Prozialeck et al. 2016) Tubular injury markers (NGAL, KIM-1) and cystatin C can be used
to detect sub-clinical acute kidney injury early, in order to adjust doses of nephrotoxic
antibiotics. (Luo, Chen et al. 2014, Ostermann 2015)
Cefepime is a popular option for the treatment of severe infections in hospitalized
patients. (Harbarth, Pittet et al. 1998) It complements the broad-spectrum armamentarium
with the ability to remain pharmacologically active against AmpC-producing organisms,
and provide a carbapenem-free option. (D'Angelo, Johnson et al. 2016) Recently, the
cephalosporins have gained favor over aminopenicillins (piperacillin-tazobactam) due to a
possible safety benefit of less association with acute kidney injury. (Rutter and Burgess
2017) Cefepime, however, is not a magic bullet free of adverse side effects. Cefepime
crosses the blood brain barrier, and can act as a competitive antagonist of gamma-amino
butyric acid (GABA), thereby inhibiting this primary inhibitory neurotransmitter system.
By way of inhibiting GABA transmission, cefepime exposure predisposes an environment
for neuroexcitation, resulting in possible seizure activity. (Payne, Gagnon et al. 2017)
Other mechanism for cefepime induced encephalopathy include the interaction with renal
transporters responsible for carnitine transport elimination. (Fernandez-Fernandez and
Ameneiros-Lago 2020) Cefepime, among other antibiotics, has been found to inhibit the
organic cation transporter OCTN2, resulting in increased excretion of carnitine in the urine,
possibly resulting in a carnitine-deficient state. (Ganapathy, Huang et al. 2000) Hypo-
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carnitine associated cephalosporin neurotoxicity has been reported previously with
cefditoren. (Kim, Chu et al. 2012)
The use of therapeutic drug monitoring to identify patients at risk for cefepime
neurotoxicity has gained attention in recent years. For centers that routinely perform these
measurements, reporting a correlation with a therapeutic range would assist clinicians in
dose adjusting to avoid this unwanted adverse effect. A Swiss study published the findings
of cefepime TDM and association with neurotoxicity (Huwyler, Lenggenhager et al. 2017)
in 2017. In this single-center retrospective study, 161 cefepime levels were drawn from 93
hospitalized patients. The hospital protocol includes a serum trough concentration to be
drawn within 1 hour of the next dose. In this center, the creatinine clearance was estimated
using the MDRD equation. The primary outcome was clinical toxicity, which was
independently assessed by two investigators, a clinical pharmacologist and an infectious
disease physician. Causality was assessed with the WHO-Uppsala Monitoring Centre
system, a standardization assessment tool for causality of a medication side effect.
Secondary study outcomes included cefepime failure, and over-dosing. The most
commonly administered cefepime dose was 6 grams a day for patients with a CrCl
>60ml/min. Renal dosing was not performed for 10% of these cases. The median trough
concentration for those receiving 4 grams a day was 11.5 mg/L (IQR 5.6-22.3), and for
those receiving 6 grams a day was 20.9 mg/L (IQR 12.4-43.5). Ten patients experienced a
neurological event, and one patient experienced a rash attributed to cefepime therapy. Of
the 10 patients with a neurological event, none fulfilled the formal assessment criteria as
they all had other possible causes, including other neurotoxic drugs, or conditions. The
most common event was confusion (n=5), altered cognition (n=4), followed by seizures
(n=1). Neurotoxicity was associated with longer days of cefepime therapy (mean duration
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8 ± 6.7) vs. 13 days (± 14.2), p =0.071; and higher serum trough levels 52.2 mg/L ± 8.4)
vs. 21.3 mg/L± 19.2, p<0.001. For those receiving continuous infusions, the steady state
concentration was higher in the neurotoxicity group, however did not reach statistical
significance, likely due to lower sample size (n=4), mean steady state concentration 48.8
mg/L± 35.3 vs. 33.8 mg/L ± 24.6. There were no toxic events at a level of <35mg/mL.
Overall, the probability of neurotoxicity increased with increasing serum trough
concentrations. (Figure 1.5) Other characteristics associated with neurotoxicity were
failure to adjust dosages for renal function, admission to an ICU, and febrile neutropenia
treatment.
Figure 1.5 Probability of neurotoxicity with increasing cefepime trough concentrations

A retrospective study, conducted at a center which routinely performs beta-lactam
TDM guided dosage optimization of meropenem and piperacillin, evaluated the impact of
higher than labeled dosing of beta-lactam on the incidence of toxicity (McDonald, Cotta et
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al. 2016). The TDM protocol calls for adjusting the total daily dose by decreasing the
dosing interval, to achieve a PK/PD goal of unbound concentration above the MIC
(fT>1xMIC) for 100% of the dosing interval. Thus, to achieve this goal, the dosing could
have exceeded the package insert labeled maximum dose. In this study, high dose was
defined as meropenem >6 grams a day for central nervous system infection, or >3 grams a
day for routine infections. Piperacillin high dose was defined as >16 grams a day.
Neurotoxicity, nephrotoxicity, hepatotoxicity, and hematological toxicity were assessed.
Ninety-three patients were included in this study (meropenem= 47 and piperacillin = 46).
The mean daily doses were 40% higher in the high dose group, as compared to the licenseddose group. Both groups achieved the PK/PD target goal, and there were no differences in
treatment course duration, or patient outcomes. There were no statistically different
differences in the seizure, renal dysfunction, hepatotoxicity or neutropenia incidence
between the two groups. This study has marked strengths and limitations. The pragmatic
evaluation of an ICU protocol increases external validity. Targeting the same PK/PD
parameter for all patients removed the confounding of excessive drug concentrations
contributing to toxicity, although the PK/PD goal itself is debatable and will influence the
resulting trough concentrations. This study is small, single center and retrospective. Further
evaluation of these outcomes should be done in a prospective study design.
A systematic review of cefepime induced neurotoxicity was published in 2017.
(Payne, Gagnon et al. 2017) Thirty-seven citations were included, representing data from
135 patients. One study was a prospective trial, and the rest were either retrospective cohort
studies, or case reports. Patients were generally older (median 69 years old), in the ICU
(81%), with renal dysfunction (80%), and received a cefepime regimen not adjusted for
renal function (48%). Cefepime trough concentrations were reported for 13 patients
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median 38 mg/L (range 15–224). Neurotoxicity developed at a median of 4 days (IRQ 26) after initiation of cefepime, with symptom resolution at a median of 2 days (IQR 1-3)
after cefepime cessation. This review has key limitations, mainly the low-quality evidence
summarized, only allows for descriptive statistics. While, identification of risk factors for
cefepime neurotoxicity is an important step, these hypotheses should be tested in a
prospective trial.
In a recent clinical evaluation of cefepime associated neurotoxicity, cefepime
exposure within the first 48 hours was classified according to dose and renal dysfunction
estimated by Cockcroft-gault equation.

(Khan, DeMott et al. 2020) For those with

moderate renal dysfunction (CrCl 30-60ml/min), a 48h dose of ≥ 8 g was considered high,
and a 48h dose of <8g was considered low. For those with severe renal dysfunction (CrCl
11-29ml/min), high dose was defined as ≥ 4 g, and low dose was <4 grams. Cefepime
associated neurotoxicity was defined as new-onset symptoms of signs of neurologic
dysfunction “altered mental status, impaired consciousness, confusion, aphasia, agitation,
myoclonus, tremor, EEG abnormalities, seizures, or nonconvulsive or myoclonus status
epilepticus”. (Khan, DeMott et al. 2020) Overall, many patients experienced a change in
neurological status (42% vs 32% p=0.145) in the low and high exposure groups,
respectively. However, when attributing the change in neurological status to cefepime, the
incidence was lower (4% vs 10% p=0.093) in the low and high groups respectively. This
was not associated with degree of renal dysfunction. Overall, the incidence of cefepime
associated neurotoxicity was low in this study. Without the corresponding TDM
measurements, it is difficult to understand the full spectrum of risk factors present in these
toxic patients.
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Piperacillin has also been implicated for causing neurotoxicity, as described in a
retrospective cohort study of 53 ICU patients who were admitted to a center which
performs TDM. (Quinton, Bodeau et al. 2017) The patients received a continuous infusion
of piperacillin of 12 grams or 16 grams a day, according to renal function. Neurotoxicity
was considered present if the patients received at least 48h of piperacillin, not on sedation,
and the patient exhibited signs of neurologic dysfunction: confusion, coma, myoclonus,
seizures or hallucinations. Patients with neurotoxicity had a statistically significant higher
steady state concentration than those without: (159.9 mg/L versus 91.3 mg/L; P= 0.0016).
A receiver operator curve analysis suggests that a cut-off level of 157.2 mg/L provides
96.7% specificity and 52.2% sensitivity for neurotoxicity (area under the concentrationtime curve [AUC], 0.75; 95% confidence interval [CI], 0.61 to 0.89). After multivariate
adjustment for CrCl <30ml/min, vasoactive medications, sepsis, hypocalcemia, only a
piperacillin concentration (≥157.2 mg/L) remained a significant predictor of neurotoxicity,
(Odds ratio 14.86, 95% CI (1.27–173.23), p= 0.0313.
Pharmacokinetic modeling has been proposed to assist in identification of
therapeutic thresholds of cefepime concentrations to predict neurotoxicity. (Rhodes, Kuti
et al. 2016) A pharmacokinetic/toxicodynamic model was created from published cases of
cefepime neurotoxic (n=32) patients and cefepime non-toxic patients (n=22). Serum
concentrations, along with covariates including age, diagnosis, CrCl, were fit in the
simulation model. A threshold of trough 22mg/L was used a prior in the model, as it has
been previously associated with neurotoxicity. Weight was not available for all patients,
therefore when unavailable, was fixed at the median of 72 kg. Overall, the mean probability
of neurotoxicity at a trough of 22mg/L was 51.4% (95% CI 16.4- 85). Sensitivity was
16.7%, and specificity was 100% at this threshold, and the overall incidence of
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neurotoxicity was only 21.6%. Simulation results displayed a dose of 2 grams every 8 hours
had the highest probability of exceeding a trough concentration >22mg/L within the first
24h of dosing (26-56%). Classification and regression (CART) modeling was attempted to
determine if a different threshold would better predict the event of neurotoxicity; however,
due to low sample size, the investigators were unable to complete this analysis. Overall,
the threshold of 22mg/L performed with low precision to predict the incidence of
neurotoxicity in this simulated experiment. Other pharmacokinetic exposures such as total
exposure and peak concentrations should be explored as predictors for cefepime
neurotoxicity.
The exact mechanism, risk factors and concentration thresholds for development of
neurotoxicity beta-lactam treated patients are unknown. Diligent dosing according to
pathogen, MIC and organ function can help reduce excessive drug exposure and possible
toxicities. Therapeutic monitoring of beta-lactam concentrations appears to be an ideal
method of avoiding toxic drug concentrations, while optimizing bactericidal killing.
1.1.5 Therapeutic Drug Monitoring Overview: TDM of Anti-infective
Therapeutic drug monitoring is a fundamental pharmacist activity in relation to antiinfective agents. Decades of research and experience have highlighted the importance of
serum concentration monitoring in an effort to optimize efficacy and safety of agents such
as vancomycin and aminoglycosides. The strategy by which these agents are monitored
and adjusted continues to evolve. In addition, novel agents and new knowledge about older
anti-infectives have created clinical scenarios for which TDM is necessary. This section
explores contemporary strategies for TDM of anti-infectives, with common abbreviations
found in Table 1.2.
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Table 1.2 Common abbreviations in this chapter
AUC0-24

Area under the concentration-time curve over a 24-hour period

Cmax

Maximum concentration

Cpeak

Serum concentration at the end of distribution phase

fT>MIC

Free concentration time above minimum inhibitory concentration

HDEI

High-dose extended interval

MIC

Minimum inhibitory concentration

PD

Pharmacodynamic

PK

Pharmacokinetic

TDM

Therapeutic drug monitoring

T>MIC

Time above minimum inhibitory concentration

Vd

Volume of distribution

Therapeutic drug monitoring is often necessary for anti-infectives with a narrow
therapeutic index or with substantial interpatient variability displayed with standard
dosing. Clinicians need to identify specific guidelines and thresholds to serve as boundaries
or goals of therapy to optimize safety and efficacy. Many of the agents for which TDM is
routinely used may be harmful if not carefully monitored. Therefore, clinicians should
understand the relationship between serum concentrations and adverse effects. For
example, aminoglycosides are known to cause nephrotoxicity in patients with prolonged
exposure to high serum concentrations; however, toxicity may occur in patients who have
concentrations in therapeutic range. (Barclay and Begg 1994) Adjustment of the dose
based on serum concentrations and clinical PK assessment permits a more personalized
dose that should lead to safer drug exposure.
Pharmacodynamic variables that are associated with bacterial killing and clinical
efficacy can also be targets for TDM. Dosing strategies to optimize bactericidal activity by
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targeting a specific peak to MIC ratio (Cpeak: MIC) or T>MIC can be developed by first
monitoring serum concentrations and adjusting therapy to meet these goals. (Craig 1998)
Some anti-infectives exhibit marked variability between individuals. This leads clinicians
to personalize the dose considering variables such as weight, renal or hepatic function.
Classic examples of these considerations are the variability of vancomycin clearance in
relation to renal function or voriconazole as a result of hepatic function and/or
pharmacogenetic factors. Reliance on standard adjustments for these variables is not
entirely accurate and some anti-infectives do not have predictable PK for reasons other
than weight and renal function. (Udy, Varghese et al. 2012) Overall, if the serum
concentrations of an agent have good association with safety and efficacy and/or exhibit
marked and clinically relevant variability with standard dosing, the agent is likely a viable
option for TDM.
Pharmacokinetic variables can be thought of in two different ways: populationspecific or patient-specific. Population -specific PK assumes the patient is reflective of the
typical patient with regard to drug disposition, metabolism, and/or elimination. Equations
for population-specific PK variables are usually derived from PK studies of the drug.
Clinicians should be mindful of the source of these equations and whether their specific
patient would fit the population from which the equations were derived. For example, a
commonly used population elimination rate constant (Ke) for aminoglycosides was
developed using an undefined population including patients and healthy volunteers.
(Bechtol and Black 1975) It may be inappropriate for a clinician to estimate the clearance
of a patient with cystic fibrosis using this equation because patients with cystic fibrosis are
known to have different aminoglycoside clearance and were not represented in this study.
A common pitfall of the use of online calculators for aminoglycoside or vancomycin dosing
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is that the source of their calculations is often not evident (or is not sought out by the user).
This situation may lead the clinician to use population guidelines and equations that are
not appropriate for the specific patient. Practically, population-specific guidelines can be a
helpful start for clinicians when deciding on an individualized dose for a patient. However,
given the narrow therapeutic index for agents that typically require TDM, going beyond
population-specific variables is usually advisable.
Patient-specific PK guidelines can be generated by sampling serum concentrations
around a given dose. Such sampling can provide clinicians with various PK guidelines that
describe the nature of the disposition and elimination of the drug, as well as reflect the
effect of various physiologic processes on the PK of the agent. For example, evaluation of
vancomycin peak and trough concentrations not only permits the clinician to calculate the
elimination rate constant and Vd, but also to assess these values in the context of fluid
resuscitation, diuresis, acutely changing renal function, and other clinical characteristics
that may affect vancomycin PK, rendering the population-specific PK equations unusable.
Important assumptions should be acknowledged when using samples to generate patientspecific PK guidelines. Intravascular volume status, protein binding, tissue penetration, and
elimination are all assumed to be relatively constant during the sampling period (although,
in reality, fluctuation in these variables is common in acutely ill patients). Similarly,
consistency of dosing to permit a steady-state, superimposable concentration-time curve is
also assumed. Clinicians should be mindful of these assumptions when interpreting serum
concentrations and calculating PK variables. When possible, precise evaluation of organ
function and protein binding should be performed. In addition, alterations in volume of
distribution, clearance, and other PK variables may occur in critically ill patients, those at
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extremes of body weight, and other patients for whom end-organ function may be
abnormal.
The development of TDM services has provided many benefits related to cost and
patient outcomes. Numerous studies have described reductions in toxicity related to
pharmacist-directed TDM and dose individualization for various anti-infective agents,
including aminoglycosides and antifungal agents such as voriconazole. (Bechtol and Black
1975, Streetman, Nafziger et al. 2001, Touw, Neef et al. 2005, Park, Kim et al. 2012) Early
studies of TDM for aminoglycosides suggested that overall costs were lower with a TDM
approach and mortality was also reduced. (Touw, Neef et al. 2005) Similarly, TDM of
vancomycin is proven to be cost effective in oncology or intensive care patients and can
reduce the incidence of nephrotoxicity. (Bond and Raehl 2005, Touw, Neef et al. 2005)
More recently, TDM has improved the therapeutic response and reduce the occurrence of
central nervous system or hematologic toxicity of antifungal agents such as voriconazole
and flucytosine. (Pasqualotto, Howard et al. 2007, Park, Kim et al. 2012)
Creation of a standardized approach to PK monitoring and documentation is a
necessity for establishing an institution-wide TDM program. Practitioners should agree
regarding the preferred PK and PD targets. Clinical pharmacists should be involved with
creation of TDM protocols, as well as educated on protocol implementation and other
institutional standards such as extent and frequency of documentation. Education of nurses
and prescribers on proper ordering and collection of serum samples for TDM should
mitigate the occurrence of sample waste and spurious results. Collaboration with other
ancillary services such as the clinical laboratory is also necessary to validate reliable assays
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and establish policies on how supratherapeutic concentrations will be handled, such as
notifying pharmacists.
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Figure 1.6. General calculations for one-compartment, first-order elimination (eg.
aminoglycosides, vancomycin at steady state)
Patients with First-Dose Kinetics
1. Calculate patient-specific elimination rate (k):
2. Calculate the Cmax:
3. Calculate the volume of distribution (Vd):

4. Calculate the estimated steady-state peak and trough concentrations:

5. Determine if trough meets goal concentration (from protocol). If trough (calculated
above) > goal concentration, time above the MIC is 100%. If trough is less than this
concentration, calculate the time at which it fell below this concentration, and thus the
new dosing interval.
t’ = ln(Cpeak/goal conc.)/k

(t’= new dosing interval rounded to the nearest hour)

6.

Follow dosing protocol for goal assessment, and dose adjustments
Patients with Steady State Kinetics
1. Follow step 1 as above.
2. Calculate the steady state Cpeak and Ctrough from C1 and C2, respectively:

3. Calculate volume of distribution (Vd):
𝑉𝑉𝑑𝑑 =

𝑀𝑀𝑀𝑀
� �𝑥𝑥 �1−𝑒𝑒 −𝑘𝑘𝑘𝑘 � 𝑥𝑥 𝑒𝑒 −𝑘𝑘𝑘𝑘
𝑡𝑡
𝑠𝑠𝑠𝑠
𝐶𝐶𝑝𝑝𝑝𝑝
𝑥𝑥 𝑘𝑘 𝑥𝑥 (1−𝑒𝑒 −𝑘𝑘𝑘𝑘 )

t= infusion time in hours; T= time between end of infusion and Cpk
(steady state)

4. Follow steps 5,6 as above.
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Figure 1.7. Example Beta-lactam dosing protocol
Initial
dose
regimen

Goal empiric
trough
concentration
(5x MIC)

Piperacillin

4 gram
q6

≥80 mcg/ml

Cefepime

2 gram
q8

≥40 mcg/ml

Meropenem

2 gram
q8

≥10 mcg/ml

Aztreonam

2 gram
q8

≥40 mcg/ml

Drug
(3hr
infusion)

Dose adjustments <100% fT>4 MIC

Step 1. Calculate new dosing interval
required to obtain goal trough (with
equations above)
Step 2: Increase total daily dose by
decreasing dosing interval.
Step 3: Maximum doses defined as a
total daily dose 2x higher than
standard labeled doses (piperacillin 32
gram, cefepime 12 gram, meropenem
12 gram, aztreonam 12 gram)

Dose
adjustments
for elevated
levels >100%
fT>10× MIC
Step 1.
Calculate new
dose/interval
based on
patient
specific PK
parameters to
target goal
range.

Step 4: If maximum dose exceeded,
consider dual therapy
Step 5: Consider dual therapy against
resistant isolates

β-Lactams
The β-lactam class of antibiotics has widely been used as the backbone for empiric
and definitive coverage of a variety of severe infections, including sepsis. (Rhodes, Evans
et al. 2017) The TDM target for β-lactams of more than 4-fold unbound concentration
above the MIC for 100% of the dosing interval (100% f >T greater than 4 times the MIC)
has been suggested in critically ill patients. (Roberts, Paul et al. 2014, Abdul-Aziz, Lipman
et al. 2015) However, less aggressive goals for bacteriostatic activity include a T>MIC of
more than 50% of the dosing interval. (Craig 1998) Achieving the more aggressive TDM
goal has been associated with improved bacterial killing, reduced emergence of resistant
isolates, increased microbiologic cure, and improved clinical outcomes in critically ill
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patients. However, the optimal goals for therapy have not been established and should be
individualized to the patient situation. (Olofsson, Geli et al. 2005, McKinnon, Paladino et
al. 2008, Abdul-Aziz, Lipman et al. 2015, Abdul-Aziz, Lipman et al. 2017)
The largest β-lactam monitoring study to date found only 35% of ICU patients met
the TDM goal of 100% f T greater than 4 times MIC, and achieving this PK/PD goal was
associated with a 2% increase in the odds of a positive clinical out- come (OR 1.02; 95%
CI, 1.01–1.05). (Roberts, Paul et al. 2014) A recent study evaluated β-lactam
concentrations in septic patients with augmented renal clearance and found 20% (16 of 79)
of patients had suboptimal β-lactam concentrations (less than 4 times MIC). The
suboptimal serum concentrations were associated with higher rates of therapeutic failure
(16% [13 of 79]) and development of resistant organisms (15% [2 of 13]). (Carrie, Bentejac
et al. 2018) Inadequate β-lactam concentrations in the early stages of sepsis have been
associated with increased mortality in gram-negative bacterial infection. (Seyler, Cotton et
al. 2011, Aitken, Altshuler et al. 2015, Carrie, Legeron et al. 2018) The Surviving Sepsis
International Guideline recommends TDM-based optimization of all anti-infectives in
sepsis, including β-lactam antibiotics, although this recommendation is not implemented
in every health system. (Rhodes, Evans et al. 2017) (Wong, Brinkman et al. 2014)
Therapeutic drug monitoring of β-lactam antibiotics can range in intensity from
first-dose sampling—similar to first- dose sampling for vancomycin using two
measurements— to steady-state sampling (peak and trough) or using a single trough
concentration. The target concentration will depend on the β-lactam selected as well as the
MIC of the likely pathogen, if known. Available dosing protocols are limited in the
literature; however, a reasonable approach for sampling tends to be a serum trough for
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intermittent infusions or a steady-state random sample for continuous infusion dosing
regimens. Calculations for PK will be similar to other anti-infectives, such as elimination
constant, the lowest concentration, which is the trough or nadir before next dose, termed
Ctrough, and Cmax, from which the T>MIC can be established. (Figure 1.6 and Figure 1.7)
Adjusting the dosing interval is a strategy that has been suggested to achieve PD goals in
patients who are not in the target range. (Roberts, Ulldemolins et al. 2010) More data are
needed to guide best practices with TDM and dose optimization in this setting because
toxicities, such as neurotoxicity, are also evident with higher concentrations of these
agents.(Durand-Maugard, Lemaire-Hurtel et al. 2012, Quinton, Bodeau et al. 2017)
The use of a continuous infusion or prolonged infusion will optimize the f T>MIC
variable. However, without increasing the total daily dose, the more aggressive PD target
of f T > than 4 times MIC is difficult to achieve. (Carrie, Legeron et al. 2018) A study in
59 critically ill patients evaluated continuous infusion piperacillin/tazobactam on target
attainment at varying MICs. Doses of 22.5 g/24 hours were required to achieve target
attainment with high MICs and when the glomerular filtration rate was greater than 170
mL/minute. (Carrie, Legeron et al. 2018) Considering these factors, critically ill patients,
who are more likely to benefit from aggressive β-lactam dosing, are also most likely to
display altered PK/PD profiles. Dose optimization on the basis of TDM is a strategy to
overcome challenges with variable dose responses in select populations.
Therapeutic drug monitoring is squarely within the pharmacist’s domain in patient
care. Use of TDM can optimize safety and efficacy for potentially toxic anti-infectives with
a narrow therapeutic index, particularly in patients at risk of toxicity or therapeutic failure,
such as those on concomitant nephrotoxins, critically ill and immunosuppressed patients,
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and patients requiring prolonged durations of therapy. The art and science of TDM requires
practice with the PK equations and careful attention to the assumptions and pitfalls of the
commonly used strategies for monitoring. Individualization of therapies beyond the classic
anti-infectives (vancomycin and aminoglycosides) associated with TDM is broadening as
assay availability becomes more prevalent and the under- standing of inter- and intrapatient variability grows. Pharmacists must be attentive to these developments and remain
at the forefront of ensuring personalized, safe, and effective pharmacotherapy by using
TDM when possible.
1.1.6 Evidence for Beta-lactam Therapeutic Drug Monitoring in Critically Ill
Patients
The largest beta-lactam monitoring study to date is the DALI study “DALI: Defining
Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses
Sufficient for Critically Ill Patients?”, from an Australian group which leads the globe in
beta-lactam research. (Roberts, Paul et al. 2014) This was a multi-national, multi-center
prospective point prevalence study. Included patients were admitted to an enrolling ICU
who received a target beta-lactam antibiotic (amoxicillin/clavulanate, ampicillin, cefazolin,
ceftriaxone, doripenem, meropenem, and piperacillin/tazobactam. Patients consented into
the study, and enrollment took place on Mondays throughout the study period. Each patient
received 2 blood draws 1) mid-way though the dosing interval and 2) a trough prior to a
dose. The unbound concentration of the beta-lactam, was measured for the highly proteinbound molecules: cefazolin and ceftriaxone, otherwise total concentrations were measured.
The PK/PD targets and study outcomes for this study were 4-fold. 1) 50% f T>MIC 2) 50%
f T>4×MIC 3) 100% f T>MIC and 4) 100% f T>4×MIC. The PK/PD goal was adjusted to
the isolated bacteria/MIC for each patient. If the MIC was unknown, the standard EUCAS
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breakpoint for Pseudomonas was used. The primary clinical outcome was a positive
microbiologic outcome- defined as completion of the antibiotic course without need for reescalation to a broader or different antibiotic within 48h of cessation. A total of 384 patients
were enrolled into this study. The median (IQR) APACHE II score was 18 (13-24), and
CrCl 80ml/min (42-125). The antibiotic concentrations were calculated at 50% and 100%
of the dosing interval, and are represented by the boxplot and whisker graph in Figure 1.8.

Figure 1.8. Box and whisker plot of antibiotic concentrations at 50% (A) and 100%( B)
of the dosing interval

There was an over 500-fold concentration difference in the concentrations seen at
50% and 100% of the dosing interval. The primary outcome, (100% fT >4x MIC) was met
by 35% of patients. Achieving this PK/PD parameter was associated with a 2% increase in
the odds of a positive clinical outcome (OR 1.02, [95% CI 1.01–1.05]). (Roberts, Paul et
al. 2014)
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Table 1.3. Multivariate Logistic regression models for a positive clinical outcome at
50%>MIC and 100%>MIC

Table 1.3 displays the result of the multivariate regression models built for a
positive outcome at 50%fT>MIC and 100%fT>MIC. Hitting either target, while controlling
for other variables in the model, was associated with an increased odd of a positive clinical
outcome.
This study is the largest of its kind to demonstrate the relationship between
achieving a PK/PD target and a positive clinical outcome in an ICU patient. Many
limitations exist in this study, the lack of randomized design, the lack of intervention arm,
and the broad inclusion criteria (including medical prophylaxis patients). This study builds
the argument to embracing of TDM in the ICU.
Another large study of beta-lactam TDM was published recently by the same lead
author. (Roberts, Joynt et al. 2020) The SMARRT study was a multi-national, multi-center
study of patients requiring CRRT and beta-lactam therapy. Septic patients who require
CRRT are among the sickest in the hospital, with mortality rates over 50%. (Bagshaw,
Uchino et al. 2007) Volume overload is a commonly occurring complication, which has
negative associations with mortality in septic CRRT patients. (Woodward, Lambert et al.
2019) Volume overload, along with variations in CRRT prescribing and delivery are
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associated with variable antibiotic concentrations, and difficult to predict pharmacokinetic
response. (Seyler, Cotton et al. 2011) Patients from 29 centers had beta-lactam trough
concentrations drawn while on CRRT. The estimated GFR was calculated from the CRRT
prescription, and intrinsic clearance from urine creatinine collection tests. Clinical
improvement was determines by the treating physician, and MIC breakpoints were
determined from EUCAST published breakpoints. (EUCAST) Two PK/PD goals were
determined: 100%T>MIC, and 100%4x>MIC. Toxic concentrations were prespecified as:
piperacillin >150mg/L and meropenem >50mg/L.
The most common CRRT modality was CVVHDF (14.7%), followed by CVVHD
(36.8%), PIRRT (27.4%) and then CVVH (14.7%). The estimated GFR from the CRRT
and measured clearance was 50ml/min (range 35- 66). For the meropenem patients (187),
a trough concentration <1xMIC was associated with a 2.55-fold increase in mortality (HR
2.55, 95% CI: 1.33-4.90). Of the 160 patients who received piperacillin trough
concentrations, were not associated with mortality. Table 1.4 shows the result of the Cox
survival analysis, of antibiotic concentration, type and mortality. (Roberts, Joynt et al.
2020)
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Table 1.4 Association of trough concentrations with adjusted and unadjusted 28-d
mortality

A prospective trial of TDM dosage adjustments of beta-lactam antibiotics was done
in febrile neutropenic patients receiving piperacillin/tazobactam. (Sime, Roberts et al.
2015) 32 patients were enrolled in this trial, and were randomized to traditional dosing, or
TDM dosage optimization for a 100%T>MIC PK/PD goal. Febrile neutropenia was
defined as an oral temperature ≥38.38C (101.8F), or ≥38.08C (100.48F) for <1 hour, in the
presence of a neutrophil count <500 cells/mm3. Patients were sampled at steady state (3rd
or 4th dose), and then again immediately after any TDM changed were made. Unbound
piperacillin concentrations were calculated from the total concentration measured,
assuming a 30% protein binding. MIC specific targets were calculated, and when
unavailable, EUCAST breakpoints were used. Dosing adjustments were done by
decreasing the dosing interval by 25%-50% at the same dose. If the concentration exceeded
100%T>10xMIC, a dosage adjustment downward was done. The patients enrolled into this
study were mostly male, median age 60 (52-64), and commonly had ARC 10 (30%). The
primary outcome was reached in 25% of control patients, and 10% intervention patients at
40

first TDM, p=1. At the second TDM, this increased to 19% in control, and 69% of
intervention patients, p=0.012. At the third sampling, the intervention patients continued
to meet the primary outcome goal 70% vs. 7% control, p=0.004. Limitations of this study
were the long return time on beta-lactam levels (12h), and a relatively low starting dose of
piperacillin (4.5g every 8h over 30 minutes). Even with TDM based dosage optimization,
almost 30% of patients still did not meet the primary PK/PD goal. However, this is the first
randomized trial to demonstrate TDM based dosage adjustments can increase target
attainment in critically ill patients. Validation on a larger scale, which includes evaluation
of patient outcomes is warranted.

1.1.7 Analytic Methods
There are no FDA approved tests for beta-lactam measurements. The available
methods of measuring beta-lactam concentrations in human fluids are limited to labdeveloped tests, of which the availability, analytic method and reporting range greatly
among centers. (Carlier, Stove et al. 2015) An international survey conducted in 2013
sought to determine how many centers perform beta-lactam measurements, and use them
to improve patient care. Nine ICU centers were included in the survey result. TDM services
were managed by physicians and pharmacists alike, and were available for approximately
5 days each week. Only 1 center from the United States responded to survey, the majority
of centers performing these measurements are in Europe and Australia. Piperacillintazobactam and meropenem were the most commonly monitored drugs (100%) of units
surveyed.
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The analytic methods utilized by respondents included: bioactivity assay, HPLC/UV,
HPLC, UPLC-MS/MS, and LC-MS/MS. For the LC-MS/MS method, the accuracy
reported was 86.8%-101.5%; precision: CV was <14.6% and the accuracy reported was
86.4%-112.3%. All labs reported to meet the regulatory requirements for precision and
accuracy. Most protocols had the measurement available within the same day, and the
patients were sampled at steady-state (day 2-3 of therapy), and contained a dose adjusting
algorithm for sub-therapeutic and supra-therapeutic concentrations.
Chromatography techniques such as LC-MS/MS are associated with high equipment
cost, and require highly trained personnel, thus possibly limiting the cost-effectiveness of
this method. The bioactivity assay, is another method which is faster and easier to set up,
yet is associated with less accuracy in the presence of concomitant antibiotics. (Carlier,
Stove et al. 2015)
A 2015 review of the literature by Carlier et al identified 15 studies of published
methods of beta-lactam measurement in the literature. (Carlier, Stove et al. 2015) Of the
15 methods that used chromatographic assays: 14 used reverse phase separation, either
coupled to UV light (9/15), or mass spectrometry (6/15). Meropenem was the most
commonly measured agent (14/15), followed by piperacillin (11/15). The calibration range
varied among methods. For piperacillin, the upper limit of quantification ranged from 5
mg/L to ≥100 mg/L, and six of the methods were <100mg/L. For cefepime the limit of
quantification ranged 50-250 mg/L, and meropenem 9-200mg/L. For a drug like
piperacillin, the ideal limit of quantification is above 100mg/L, as large doses of 12-16
grams are commonly given to ICU patients. If the limit of quantification is below the
measured concentration, a dilution must be performed for quantification, which will delay
the result reaching the bedside providers. The lower limit of quantification of an assay is
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ideally below the MIC of the organism. Of these published reports, the lower limit of
quantification varied: cefepime 0.01mg/L – 2; meropenem 0.04mg/L – 2mg/L; and
piperacillin 0.005mg/L – 10mg/L. Ohmori and colleagues presented their development of
a beta-lactam method using LC-tandem MS. (Ohmori, Suzuki et al. 2011)

1.1.8 Dissertation Hypothesis and Specific Aims

Dissertation hypothesis: A major class of antibiotics used in the treatment of severe
infections which causes sepsis and septic shock are the beta-lactams antibiotics. The
underlying pathophysiology and treatments for patients with sepsis induce inter-patient
variability in the pharmacokinetic profile of beta-lactam antibiotics, which alters the ability
to achieve the goal PK/PD target attainment for severe infections.

Therapeutic drug

monitoring is a strategy to overcome the variability of the current dosing approach by
personalizing doses according to patient parameters. There are no currently FDA approved
tests to measure beta-lactam antibiotic concentrations for therapeutic drug monitoring. Our
hypothesis is that therapeutic drug monitoring for beta lactam antibiotics will overcome
the pharmacokinetic variation in patients with severe sepsis, in order to achieve the optimal
PK/PD target for severe infections.

Aim 1: To determine the impact of routine currently recommended renal dosage
adjustments in patients with septic shock due to gram negative bacteremia on patient
outcomes
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Aim 1 Hypothesis: The currently recommended renal function guided dosage regimens of
beta-lactam antibiotics in septic shock patients with acute kidney injury is associated with
fewer vasopressor-free days alive in the ICU, when compared to those who receive
unadjusted beta-lactam regimens
Aim 2: To examine the relationship of beta-lactam PK/PD target attainment achievement,
as measured by therapeutic drug monitoring, with clinical outcomes in patients admitted to
the ICU for sepsis
Aim 2 Hypothesis: Achieving the beta-lactam PK/PD target attainment (100%T>4xMIC)
is associated with improved clinical outcomes in ICU patients with sepsis as compared to
those who fail to achieve the PK/PD target
Aim 3: To develop a Laboratory Developed Test using LC-MS to measure beta-lactam
concentrations in hospitalized patients
Aim 3 Hypothesis: A Laboratory Developed Test utilizing LC-MS technology will
improve beta-lactam concentration accuracy over available detection methods, and
facilitate personalized dosing of beta-lactam antibiotics for hospitalized patients with
sepsis

CHAPTER 2. AIM 1: TO DETERMINE THE IMPACT OF ROUTINE CURRENTLY
RECOMMENDED RENAL DOSAGE ADJUSTMENTS IN PATIENTS WITH
SEPTIC SHOCK DUE TO GRAM NEGATIVE BACTEREMIA ON PATIENT
OUTCOMES
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2.1.1 Aim 1 Significance,
Rationale and Hypothesis
Sepsis is a highly deadly and prevalent disease, resulting in 750,000 annual cases, with
a mortality rate of 30%. (Rhodes, Evans et al. 2017) Timely administration of the correct
antibiotic, and in the correct dose can improve outcomes for critically ill patient with sepsis.
(Kumar, Roberts et al. 2006) (Liu, Fielding-Singh et al. 2017) Not only drug selection, but
the appropriate dose needs consideration when treating patients with sepsis. Sepsis induces
a dramatic change in the expected pharmacokinetic profile of beta-lactam antibiotics.
(Goncalves-Pereira and Povoa 2011) Especially important, are the effects of acute kidney
in sepsis on the ability to achieve therapeutic drug concentrations. In one study of AKI septic
patients, the measured volume of distribution (Vd) was 2-fold larger for daptomycin
(0.08L/kg increased to 0.23L/kg). (Khadzhynov, Slowinski et al. 2011) The PK changes in
sepsis are especially challenging for beta-lactam antibiotics, and has been linked to poor
patient outcomes. (Taccone, Laterre et al. 2010) Dosage adjustments are recommended for
patients with reduced GFR. (package inserts) However, it is prudent to understand where
these recommendations come from, and the limitation of the current regulatory approval
process. (Crass, Rodvold et al. 2019) Poor microbiological outcomes have been linked to
adherence to renal dosage adjustments in recent observations. (Kullar, Wagenlehner et al.
2017)
Aim 1: To determine the impact of routine currently recommended renal dosage
adjustments in patients with septic shock due to gram negative bacteremia on patient
outcomes
Aim 1 Hypothesis: The currently recommended renal function guided dosage regimens
of beta-lactam antibiotics in septic shock patients with acute kidney injury is associated with
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fewer vasopressor-free days alive in the ICU, when compared to those who receive
unadjusted beta-lactam regimens.

2.1.2

Aim 1 Methods Impact of
Dose Adjusted Beta-lactam
Antibiotics in the First 48h of
Sepsis Treatment: A
Retrospective Multicenter
Cohort Study

Design and Setting
To test the above hypothesis, we undertook a retrospective, observational, cohort study
of critically ill adult patients admitted to an intensive care unit at a study site who received
a broad-spectrum beta-lactam (cefepime, piperacillin/tazobactam, or meropenem) for at
least 48 hours from 1/1/2013 to 4/30/2019.
Study Population
Inclusion criteria was age 18 years ≤, admission to the ICU for at least 48h, receipt of
at least 48h of the same beta-lactam antibiotic, presence septic shock, defined according to
Sepsis-3 definition (corroborated with the receipt of a vasoactive agent), positive blood
culture with a gram negative organism, acute kidney injury at time of beta-lactam
administration, AKI was defined according to the serum creatinine and urine output KDIGO
criteria: (≥0.3mg/dL increase in serum creatinine or a total increase in ≥1.5mg/dl x baseline,
or a decrease in urine output <0.5ml/kg/hour for 6 hours. Exclusion criteria included receipt
of a continuous infusion beta-lactam, receipt of >1 beta lactam (meropenem, cefepime,
piperacillin-tazobactam), receipt of an excluded beta-lactam within 48 hours (zebaxa,
vabomere, avycaz), CRRT initiation within 48h of beta-lactam receipt, ECMO, transfer
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from outside facility, non-susceptible cultured microorganism, concomitant gram-positive
infection.
Definitions and Outcomes
The Cockcroft and Gault equation was used to estimate glomerular filtration rate (GFR)
from serum creatinine. (Cockcroft and Gault 1976) Patients were grouped according to the
dosing classification of the first 48 hours of therapy into 1) Adjusted or 2) Unadjusted.
(Table 2.1). The primary study outcome was shock free survival up to 28d. Secondary
outcomes included all-cause mortality at 28d, ventilator-free days at 28d, ICU length of stay
and hospital length of stay. Shock free survival and ventilator free days were calculated as
previously defined. (Yehya, Harhay et al. 2019) Several prior sub-group analyses of the
primary outcome were planned: beta-lactam type, source of bacteremia, and infecting
organism, and severity of AKI (GFR <50ml/min).
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Table 2.1 Grouping scheme according to dosing classification of the first 48 hours of
therapy

Beta-lactam

Cefepime
(CEF)

Piperacillintazobactam
(PTZ)
Meropenem

Severe AKI

Mild AKI

CEF GFR 11-29 ml/min
PTZ GFR 10-19 ml/min
MEM GFR 10-25 ml/min

CEF GFR 30-60 ml/min
PTZ GFR 20-40 ml/min
MEM GFR 26-50 ml/min

Unadjusted ≥ 4 g EI or II

Unadjusted ≥8 g

Adjusted < 4g EI or II

Adjusted < 8 g

Unadjusted ≥ 18g EI or II

Unadjusted ≥ 20.25g EI or 27g II

Adjusted <18g EI or II

Adjusted < 20.25g EI or 27g II

Unadjusted ≥ 4 g EI or II

Unadjusted ≥6 g

Adjusted amount < 4g EI or II

Adjusted < 6 g

(MEM)

Statistical Analysis
Continuous variables were tested for distribution by histogram visualization and with
the Shapiro-Wilk test. Continuous variables with normal distribution are presented as mean
(SD); otherwise are presented as median (IQR). Continuous variables were analyzed using
either the Student’s T-test or the Wilcoxon Rank-sum test as appropriate. Categorical
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variables are presented as frequencies and proportions and analyzed using the Pearson’s
Chi-square or Fisher’s Exact test as appropriate.
Multivariable logistic regression was used to assess the effects of independent
variables on the primary outcome, shock free survival, and secondary outcome mortality.
All variables displaying a difference in the bivariate analysis (<0.2) were included for
consideration into the final multivariable model, along with standard demographic/critical
illness parameters, and variables identified a priori, or known to impact the outcome (e.g.,
timing of beta-lactam initiation, KDIGO stage, bacteria type).
The models were tested for assumptions of logistic regression as appropriate.
Multicollinearity was tested using variance inflation factor (<2.5); normality of errors was
assessed with the IQR test and visualization with the kernel density estimate. Constant
variance

by

assessment

with

the

Breusch-Pagan

/Cook-Weisberg

test

for

heteroskedasticity, and was adjusted using robust standard errors if appropriate. Model fit
was assessed with the Hosmer-Lemeshow goodness of fit test. All other assumptions were
met. Statistical analyses were done using Stata (version 14.2, Stata Corp, College Station,
Texas, USA)
2.1.3

Aim 1 Results

Clinical Characteristics
A total of 179 patients were included in the final analysis (103 in the adjusted group,
76 in the unadjusted group). The subjects were evenly split with regards to gender (male)
49 (48%) vs. 41 (54%), p= 0.399, unadjusted vs adjusted respectively. The median age in
years was 65 (50-74) unadjusted vs. 64 (58-74) adjusted, p= 0.245. The majority of patients
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were admitted to a medical ICU >70% both groups, p=NS. Admission SOFA was 9 (5-11)
in the unadjusted vs. 8 (5-10.5) in the adjusted group, p=0.864. KDIGO stage 1 AKI was
the most common stage of AKI in both groups >50% both groups, however the serum
creatinine at beta-lactam initiation was higher in the adjusted group 1.94 (1.29- 3.15) vs.
1.48 (1.08- 2.02) unadjusted, p <0.006. The most common source of infection was intraabdominal 34% total cohort, followed by urinary 30% total cohort, followed by pulmonary
(12% total cohort), p=0.474. The most commonly isolated bacterium was E.coli (44%),
followed by K. pneumoniae (24%), and then P. aeruginosa (23%). Patients in the
unadjusted group were more likely to have the beta-lactam antibiotic given within 1 hour
of cultures drawn 52% vs. 45%, p=0.309. Baseline demographics are found in Table 2.2,
baseline disease severity characteristics are found in Table 2.3, treatment characteristics
are found in Table 2.4, Beta-lactam doses and infusion strategies are found in Table 2.5,
and in Table 2.6, additional treatment characteristics.
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Table 2.2 Baseline Characteristics
Characteristic

Total (n=179)

Age (y), mean ± SD
Sex (m), n (%)
Weight (kg), mean
± SD
BMI (kg/m2), mean
± SD

64.5 (53-74)
90 (50%)
78 (61.3- 92)

Unadjusted
(n=103)
65 (50-74)
49 (48%)
78.9 (62- 94)

26.6 (21.8- 31.1)

26.45 (22.6- 30.9)

Medical/respiratory
Surgical (nontrauma)
Trauma
Cardiac/surg
Cardiac (nonsurgery)
ED
Floor/PCU
Other
Past medical
history, n (%)
CHF
CKD without
dialysis
HTN
Liver disease
COPD
Immunosuppressed
(ANC 500 at
admission)
Neurological
disorder (seizures,
dementia, prior
stroke)
SOT
Malignancy (active)
DM
Other chronic lung
condition

Admission ICU, n (%)
129 (72%)
76 (74%)
31 (17%)
14 (14%)
8 (4%)
3 (2%)
8 (4%)

6 (6%)
2 (2%)
5 (5%)

Adjusted
(n=76)
64 (58-74)
41 (54%)
74.65 (59.5591.3)
26.97 (20.8831.81)

p-value

53 (70%)
17 (22%)

0.521

0.245
0.399
0.511
0.848

2 (3%)
1 (2%)
3 (4%)

Admissions source
116 (74%)
70 (68%)
40 (22%)
20 (19%)
23 (13%)
13 (13%)

46 (61%)
20 (26%)
10 (13%)

0.518

33 (18%)
28 (16%)

16 (16%)
13 (13%)

17 (22%)
15 (20%)

0.244
0.195

99 (55%)
27 (15%)
18 (10%)
27 (16%)

52 (51%)
14 (14%)
7 (7%)
16 (16%)

47 (625)
13 (17%)
11 (15%)
11 (15%)

0.131
0.516
0.091
0.766

29 (17%)

18 (18%)

11 (14%)

0.590

5 (3%)
74 (41%)
51 (29%)
18 (10%)

2(2%)
43 (42%)
26 (25%)
11 (11%)

3 (4%)
31 (41%)
25 (33%)
7 (9%)

0.421
0.898
0.262
0.747
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Table 2.3 Disease severity characteristics
Disease severity

Total (n=179)

Unadjusted
(n=103)

Adjusted
(n=76)

pvalue

2.33 (0.69)

2.40 (0.73)

2.23 (0.63)

0.114

3.8 (2.25- 6.1)

3.85 (2.4- 6.1)

3.7 (1.8- 6.1 )

0.381

8 (5-11)

9 (5-11)

8 (5-10.5)

0.864

80 (46%)

39 (40%)

41 (54%)

0.072

102 (57%)
42 (23%)
35 (20%)

62 (60%)
27 (26%)
14 (14%)

40 (53%)
15 (20%)
21 (28%)

Baseline Scr

0.88 (0.65- 1.08)

0.82 (0.6- 1.03)

0.0661

SCr at beta-lactam
initiation, median (IQR)

1.62 (1.23- 2.56)

1.48 (1.08- 2.02)

0.9 (0.751.28)
1.94 (1.293.15)

Scr 24h

1.67 (1.14- 2.55)

1.54 (1.07- 2)

0.0001

Scr 48h

1.42 ( 0.94- 2.49 )

1.2 (0.9- 2.13)

CG CrCl at beta-lactam
initiation, mean ± SD

46 (27-66)

50 (33- 67)

2.10 (1.422.99)
1.96 (1.122.84)
37 (22-58 )

CrCl at 24 h, mean ± SD

46 (28-65)

51 (32-71)

36 (24- 56)

0.0004

CrCl at 48 h, mean ± SD

50 (29- 79)

57 (36- 90)

41 (25- 69)

0.0030

77 (43%)

47 (46%)

30 (40%)

0.411

Albumin at beta-lactam
initiation (mg/dL), mean ±
SD
Peak lactate median
(IQR)
SOFA score at ICU
admission
Mechanical ventilation
within 24 hours of betalactam initiation, n (%)
AKI stage at initiation, n
(%)
Stage 1
Stage 2
Stage 3

Renal recovery within 48h
n(%)
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0.060

0.0060

0.0022
0.0076

Table 2.4 Treatment Characteristic
Treatment Characteristic

Total (n=179)

Unadjusted
(n=103)

Adjusted (n=76)

pvalue

Pulmonary

20 (12%)

13 (12%)

7 (10%)

0.474

Intra-abdominal

57 (34%)

34 (35%)

23 (33%)

Renal/GU

50 (30%)

24 (34%)

26 (27%)

SSTI

10 (6%)

8 (8%)

2 (3%)

CNS

1 (1%)

0 (0%)

1 (1%)

Bone/joint

1 (1%)

1 (1%)

0 (0%)

Unknown

30 (18%)

16 (16%)

14 (20%)

Gram negative organism, n
(%)
E. coli

78 (44%)

41 (40%)

37 (49%)

K. pneumoniae

43 (24%)

28 (27%)

15 (20%)

K. oxytoca

2 (2%)

1 (1%)

1 (1%)

E. cloacae

9 (5%)

6 (6%)

3 (4%)

P. aeruginosa

23 (23%)

13 (13%)

10 (13%)

A. baumanii

1 (1%)

0 (0%)

1 (1%)

B. cepacia

1 (1%)

1 (1%)

0(0%)

C. spp

4 (2%)

3 (3%)

1 (1%)

Proteus spp.

7 ( 4%)

4 (4%)

3 (4%)

Other

11 (6%)

6 (6%)

6 (7%)

Organism (2) n(%) (Total 17)

17 (9%)

12 (11%)

5 (7%)

0.082

Piperacillin MIC

8 (4-16)

8 (4-16)

8 (4-16)

0.069

Cefepime MIC

2 (1-2)

2 (1-2)

2 (1-2)

0.083

1 (0.25-1)

1 (0.25- 1)

1 (0.25-1)

0.851

72 (41%)
87 (50%)
15 (9%)

43 (43%)
51 (51%)
6 (6%)

29 (39%)
26 (49%)
9 (12%)

88 (49%)

54 (52%)

34 (45%)

0.309

1.16 (0.08- 7.8)

0.8 (0.067-6.35)

1.85 (0.9114.33)

0.319

53 (30%)
42 (23%)
84 (47%)

33 (32%)
14 (14%)
56 (54%)

20 (26%)
28 (37%)
28 (37%)

Source of infection

Meropenem MIC
Location of patient at first
dose
ICU
ED
Floor
Beta-lactam given within 1
hour of cultures
Median time from cultures
drawn to BL given
Beta-lactam received
Cefepime
Meropenem
Piperacillin/tazobactam

53

0.852

0.355

0.001

Table 2.5 Beta-lactam doses and infusion strategy
Dose/strategy
Piperacillin/tazobactam
Initial Piperacillin/tazobactam
dose
EI strategy, n (%)

Total (n=
179)

Unadjusted
(n=103)

Adjusted
(n=76)

p-value

3.64 (0.75)

3.61 (0.73)

3.69 (0.80)

0.648

47/84 (56%)

31/56 (55%)

16/28 (57%)

0.876

Amount in first 24 h (g), mean ±
SD
Amount in first 48 h (g), mean ±
SD
Total amount in first 48h (g), mean
± SD
Cefepime

12.38 (4.06)

12.48 (3.89)

10.21 (3.54)

<0.001

11.75 (3.9)

12.37(3.74)

10.47 (4.2)

0.039

24 (7.39)

25.85 (6.54)

20.29 (7.71)

<0.001

EI strategy, n (%)

13/ 53 (25%)

2/33 (6%)

11/20 (55%)

<0.001

Initial cefepime dose

1.59 (0.49)

1.75 (0.44)

1.35 (0.49)

0.0036

Amount in first 24 h (g), mean ±
SD
Amount in first 48 h (g), mean ±
SD
Total amount in first 48h (g), mean
± SD
Meropenem

3.85 (1.96)

4.87 (1.67)

2.15 (0.98)

<0.001

3.64 (1.73)

4.57 (1.43)

2.1 (0.85)

<0.001

7.49 (3.4)

9.45 (2.67)

4.25 (1.74)

<0.001

Initial meropenem dose

0.88 (0.34)

1 (0.33)

0.82 (0.33)

0.116

EI strategy, n (%)

3/41 (7%)

1/14 (7%)

2/27 (7%)

0.975

Amount in first 24 h (g), mean ±
SD
Amount in first 48 h (g), mean ±
SD
Total amount in first 48h (g), mean
± SD

2.3 (0.97)

3.07 (0.97)

1.98 (0.75)

<0.001

2.15 (0.91)

2.9 (1.0)

1.78(0.55)

<0.001

4.5 (1.78)

5.96 (1.98)

3.77 (1.13)

<0.001
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Table 2.6 Additional Treatment Characteristics
Characteristic

Total (179)

Unadjusted
(n=103)

Adjusted
(n=76)

pvalue

Receipt of additional antibiotic
with significant activity against
MDR-GN within 48 h of betalactam initiation, n (%)
Aminoglycoside, n (%)

90 (51%)

49 (49%)

41 (54%)

0.474

45 (25%)

28 (27%)

17 (22%)

0.463

Fluoroquinolone, n (%)

25 (14%)

10 (10%)

15 (20%)

0.056

1 (1-2)

1 (1-2)

1 (1-2)

0.728

174 (97%)

100 (97%)

74 (97%)

0.910

Epinephrine

15 (8%)

6 (6%)

9 (12%)

0.151

Vasopressin

46 (26%)

28 (27%)

18 (24%)

0.596

Phenylephrine

14 (8%)

8 (8%)

6 (8%)

0.975

Dopamine

3 (2%)

2 (2%)

1(1%)

0.747

9.14 (5-20.79)

10.5 (4.916.38)

8.9 (5-24.1)

0.339

18 (7-33.4)

17.64 (6-30.93)

18.5 (7.9135.83)

0.271

7.8 (0.2- 20)

9 (1.26- 23.92)

7.25 (0-17.77)

0.342

53 (31%)

27 (27%)

26 (36%)

0.225

14 (8%)

7 (7%)

7 (9%)

0.547

2670 (11754621)

2802 (12494668)

2190 (9334452)

0.465

1080 (1842680)

993 (85- 2760)

1274 (1892680)

0.951

Number of IV vasopressor(s)
received during initial episode of
shock (n), median (IQR)

Vasopressor(s) received during shock, n (%)
Norepinephrine

Norepinephrine equivalents at
beta-lactam initiation (NEQ
mcg/kg/min), median (IQR)
Maximum NEQ (for at least 1 h)
in first 48 h after beta-lactam
initiation (NEQ mcg/kg/min),
median (IQR)
Change in pressor dose initial to
max
Hydrocortisone ≤300 mg/d, n
(%)
IV thiamine ≥400 mg/d, n (%)
Net fluid balance in first 24 h
after beta-lactam initiation (mL),
median (IQR)
Net fluid balance in second 24 h
after beta-lactam initiation (mL),
median (IQR)

55

Primary Outcomes
The primary outcome of shock-free survival at 28d was not different between the two
groups: 25.56 days (0-27.16) unadjusted, vs. 25.32 days (0-27.04) adjusted, p=0.799. By
28 days 38 patients (37%) in the unadjusted group died, and 26 patients (34%) in the
adjusted group died, p=0.77. VFD-28 was not different between groups, 26.74 days (028) vs. 26.45 days (0-28), unadjusted vs. adjusted accordingly. ICU and hospital length of
stay were not different between groups, Table 2.7.
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Table 2.7. Primary study outcomes
Outcome

Total
(n=179)

Unadjuste
d (n=103)

Adjusted
(n=76)

OR

95% CI

Duration of shock-free
survival in the first 28
days (d), mean ± SD
Duration of MV-free
survival in the first 28
days (d), mean ± SD
Duration of MV-free
survival in the first 90
days (d), mean ± SD
ICU mortality, n (%)

25.54 (027.06)

25.56 (027.16)

25.32 (0-27.04)

0.452

-3.043.95

26.48 (0-28)

26. 74 (028)

26.45 (0-28)

0.02

-3.673.7

0.648

87.02 (0-90)

86.11 (090)

87.09 (0-90)

2.92

-9.5515.40

0.644

48 (27%)

26 (25%)

22 (29%)

1.21

0.580

65 (36%

38 (37%)

26 (34%)

0.88

5.83(2.9211.99)
12.81 (6.9523.92)

5.5 (2.7510.74)
11.95 (6.3122.06)

2.66

0.622.35
0.481.65
-29.2434.58
-4.8852.52

65 (87%)

1.37

0.593.18
0.1641.878
0.4566.837
0.5071.851

0.454

0.1863.479

0.772

28-day mortality, n
(%)
ICU LOS (d)

Shock resolved during
ICU stay
CRRT, n (%)

150 (84%)

5.92 (3.0412.83)
12.83
(7.1624.98)
85 (82%)

13 (7%)

9 (9%)

4 (5%)

0.56

Dialysis dependent at
discharge n (%)
Return of renal
function to baseline, n
(%)
CDI, n (%)

9 (6%)

4 (4%)

5 (7%)

1.76

114 (67%)

66 (67%)

48 (67%)

0.969

8 (4%)

5 (5%)

3 (4%)

0.805

Hospital LOS
(d)
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23.81

pvalu
e
0.799

0.77
0.457
0.768

0.344
0.405
0.926

Multivariate regression modeling
The results of the multivariate linear regression for pressor free days at 28d is found in
Table 2.8. Controlling for all variables in the model, three variables emerged as statistically
significant predictors of pressor-free days at 28d: lactate, KDIGO stage 2 AKI, and
maximum vasopressor dose. For every 1-unit increase in lactate, the number of pressor free
days decreased by 0.97 (β -0.97, [95% CI -1.67, -0.27], p=0.007). KDIGO Stage 2 AKI
was associated with 7.77 fewer pressor-free days, as compared to KDIGO Stage 1, (β -7.77,
[95% CI 13.15, -2.40], p= 0.005). For every mcg/kg/min unit increase in maximum
vasopressor dose, the number of vasopressor-free survival days decreased by 0.07 (β -0.07,
[95% CI -0.13, -0.01], p=0.033).
The multivariate logistic regression for mortality is shown in Table 2.9. Peak lactate,
Stage 2 AKI, and immunosuppressed on admission were all associated with increased
mortality. Every 1-unit increase in peak lactate, was associated with an 18% increase in
mortality (OR 1.18, [95% CI 1.00, 1.38], p= 0.047). KDIGO Stage 2 AKI was associated
with a 456% increase in mortality, when compared to those with KDIGO stage 1 AKI (OR
4.56, [95% CI 1.33, 15.69], p=0.016). Those who were immunosuppressed on admission
(ANC <500) had a 4.47 -fold increase in mortality, as compared to those with an ANC
>500, (OR 4.47, [95% CI 1.13, 17.65], p=0.032).
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Table 2.8. Multivariate linear model for pressor free days at 28d.
Variable

β Coef

P>|t|

Adjusted BL dose
Age
Male gender
Lowest serum albumin
Peak serum lactate
SOFA score
KDIGO Stagea
Stage2
Stage 3
Immunosuppressed at admission (ANC <500)

-2.11
0.03
2.14
1.96
-0.97
-0.16

0.356
0.334
0.334
0.289
0.007
0.643

95% Confidence
Interval
-6.62, 2.41
-2.23, 6.52
-2.24, 6.52
-1.69, 5.62
-1.67, -0.27
-0.86, 0.53

-7.77
1.03
-2.28

0.005
0.727
0.455

13.15, -2.40
-4.78, 6.83
-8.32, 3.76,

Beta-lactam Giving within 1hour of cultures

-2.15

0.347

-6.66, 2.36

Bacteria Isolatedb
K. pneumoniae
E. cloacae
P. aeruginosa
B. cepacia
C. spp
Proteus spp.
Other
Extended Infusion

-0.34
-3.76
-6.26
11.47
9.13
-4.24
-7.72
3.08

0.902
0.498
0.052
0.335
0.265
0.613
0.096
0.257

-5.74, 5.06
-14.77, 7.24
-12.58, 0.06
-12.05, 34.99
-7.04, 25.30
-20.84, 12.34
-16.84, 1.40
-2.28, 8.44

Double coverage of non- BL

-0.75

0.772

-5.87, 4.37

Maximum pressor dose in NE equivalents

-0.07

0.033

-0.13, -0.01

24h fluid balance

0.00

0.246

-0.00, -.001

Referent category KDIGO stage 1
Referent Category E. coli
Model Adj R2= 0.21 p=0.002 Obs 114

a
b
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Table 2.9. Multivariate logistic model for mortality
Variable

Odds Ratio

P>|t|

Adjusted BL dose
Age
Male gender
Lowest serum albumin
Peak serum lactate
SOFA score
KDIGO Stagea
Stage2
Stage 3
Immunosuppressed at admission (ANC <500)

1.10
1.00
0.42
0.84
1.18
9.89

0.839
0.809
0.092
0.665
0.047
0.131

95% Confidence
Interval
0.41, 2.99
0.97, 1.03
0.15, 1.15
0.38, 1.85
1.00, 1.38
0.75, 1.04

4.56
1.38
4.47

0.016
0.613
0.032

1.33, 15.69
0.38, 4.96
1.13, 17.65

Beta-lactam administered within 1 hour of
cultures

1.32

0.589

0.47, 3.72

Bacteria Isolatedb
K. pneumoniae
E. cloacae
P. aeruginosa
Proteus spp.
Other
Extended Infusion

0.70
0.44
3.66
0.95
3.63
0.46

0.575
0.553
0.055
0.979
0.172
0.223

0.21, 2.35
0.03, 6.36
0.97, 13.80
0.04, 22.85
0.57. 23.20
0.13, 1.59

Double coverage of non- BL

1.07

0.901

0.34, 3.39

Maximum pressor dose in NE equivalents

1.02

0.060

0.99, 1.04

24h fluid balance

0.99

0.948

0.99, 1.00

Referent category KDIGO stage 1
Referent Category E. coli
Model R2= 0.21 p=0.031 Obs 111

a
b

Secondary outcomes
Several prior sub-group analyses of the primary outcome were planned, including betalactam type, infection with Pseudomonas spp, and categorizing GCR <50ml/min. There
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were no differences seen in any of the three primary outcomes, with regards with any subgroup. (Table 2.10) Patients with a CrCl <50ml/min at the time of beta-lactam initiation
were analyzed in multivariate regression. Controlling for other variables in the model,
including sofa score, bacteria isolated, immune status, those with a dose adjusted betalactam had 6 fewer days alive and free from vasopressors than those without dosage
adjustment in the first 48h, (β -5.94, [95% CI -11.07, -0.81], p=0.042). The full multivariate
model is found in Table 2.11.
Table 2.10 Sub-group analysis of primary and secondary outcomes
Sub-group
(n)

Outcome
Median (IQR)

Unadjusted

Adjusted

P-value

GFR
<50ml/min
(100)

Shock-free
survival at 28h

25.6 (20.95- 27.16)

26.01 (0-27.38)

0.775

VFD-28

26.39 (13.25-28)

26.42 (0-28)

0.380

Mortality

17/51 (33%)

19/49 (39%)

0.571

Shock-free
survival at 28h

26.28 (0-27.54)

24.89 (10.2526.73)

0.281

VFD-28

28 (0-28)

26.46 (10.41-28)

0.725

Mortality

11/33 (33%)

6/20 (30%%)

0.801

Shock-free
survival at 28h

25.43 (0-26.61)

26.02 (20.9426.88)

0.550

VFD-28

24.21(0-28)

26.73 (13.86-28)

0.564

Mortality

21/56 (38%)

7/28 (25%)

0.252

Shock-free
survival at 28h

25.74 (22.38-26.78)

25.32 (0-27.44)

0.759

VFD-28

28 (0-28)

24.69 (0-28)

0.251

Mortality

9/14 (43%)

13/28 (46%)

0.826

Shock-free
survival at 28h

23.45 (0-26.38)

24.51 (0-26.59)

0.897

VFD-28

0 (0-28)

25.74 (0-28)

0.548

Mortality

10/13 (77%)

4/10 (40%)

0.072

Cefepime (53)

Piperacillintazobactam
(84)

Meropenem
(41)

Pseudomonas
(23)
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Table 2.11. Multivariate Linear regression model of shock-free survival in patients with a
CrCl <50ml/min
Model of shock free survival, limited to CrCl
<50ml/min at time of BL dose
Variable
Dose adjusted BL

β coef.

P>|t|

95% Confidence
Interval

-5.94

0.024

-11.07, -0.81

Peak lactate

-0.83

0.085

-1.79, 9.11

SOFA score
Immunosuppressed at admission (ANC <500)
Beta-lactam administered within 1 hour
Bacteria Isolatedb
K. pneumoniae
E. cloacae
P. aeruginosa
C. spp
Proteus spp.
Other
Extended Infusion

-0.003
-1.29
-2.97

0.993
0.757
0.273

-0.77, 0.76
-9.64, 7.05
-8.35, 2.41

-2.55
-14.16
-12.97
0.87
-23.43
-13.24
-0.59

0.499
0.024
0.001
0.933
0.027
0.005
0.845

-9.39,4.21
-26.43, -1.89
-20.12, -5.81
-20.06, 21.81
-44.09, -2.76
-22.34 -4.15
-6.65, 5.46

Maximum pressor dose in NE equivalents

-0.06

0.086

-0.12, 0.00

24h fluid balance

0.00

0.129

-0.00, 0.00

Referent Category E. coli
Model R2 0.25, p = 0.03, Obs 66
b

2.1.4

Aim 1 Discussion and
Conclusion

Dose adjusting of cefepime, piperacillin-tazobactam or meropenem was not associated
with clinical outcomes in this cohort of critically ill patients with septic shock and AKI
(KDIGO stage1 and higher). In a prespecified sub-group of those with a CrCl <50ml/min
at the time of beta-lactam initiation, dosage adjustment was statistically significantly
associated with fewer days alive and free from vasopressor agents. These finds are
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supported by previous observations made by Kullar and colleagues, where an exploratory
analysis of a predefined cut point of <50ml/min was associated with poor microbiological
response in patients enrolled in the ASPECT trials (complicated intra-abdominal infections
and complicated urinary tract infection) trials. (Kullar, Wagenlehner et al. 2017) The
patients in ASPECT-cIAI and cUTI et al were less critically ill, than our current population.
(Solomkin, Hershberger et al. 2015, Wagenlehner, Umeh et al. 2015) Fewer than 10% had
bacteremia, and the >80% had an APACHE of <10. Of the patients in both trials, a
combined 94 (36 from ASPECT-cIAI and 58 from ASPECT-cUTI) had a CrCl <50ml/min
on admission.
The construct of transient AKI has been discussed in expert circles of late, with the
premise that dosage adjusting should not occur in a patient with a transient AKI. In a large
retrospective study by Crass et al, records of patients with infections requiring antibiotics
were reviewed for rates of transient AKI. (Crass, Rodvold et al. 2019) Of 18,650 records
reviewed, 17.5% (3256) had AKI on admission. Of those with AKI on admission, 57.2%
were transient, recovering with in 48h of index admission. A leading hypothesis as to the
nature of these observations of improved microbiologic and clinical outcomes in nondosage adjustments, is the notion that transient AKI does not require dose adjusting of a
beta-lactam antibiotic. (Crass, Rodvold et al. 2019) Therefore, according to the above
authors, in the presence of rapid recovery of renal function, and severe infections- dose
adjusting the beta-lactam should not be recommended. The total dose of beta-lactam over
the first 48h may be an important predictor of microbiologic and clinical outcomes in larger
cohorts, as seen in Figure 2.1.
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Figure 2.1 Linear relationship between total grams of beta-lactam received in the first 48h
and shock-free survival at d28.
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Making dosing decisions based on serum creatinine in critically ill patients has been
criticized for a long time. Serum creatinine-based equations are limited to interpretation in
populations with steady production and elimination of creatinine. (Baptista, Neves et al.
2014) Critically ill patients with sepsis requiring antibiotics exhibit dynamic Pk
parameters, including rapid changed in Vd and Cl. The wide therapeutic index of betalactam drugs, coupled with the emerging data of harm due to under dosing should compel
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the clinician to re-evaluate empiric these dosage adjustments. Without direct TDM of betalactam antibiotics, full labeled dosing should be used in all patient with septic shock.
We did not evaluate microbiologic outcomes in this current study, as we hypothesized,
in a sicker population a difference in a hard-clinical outcome such as days alive and free of
vasopressors could be observed. However, when solely evaluating the group of patients
with a CrC <50ml/min (n= 100), the data were underpowered to detect a difference in
mortality. Future studies testing this hypothesis should use the cut of off (CrCl<50ml/min)
as the defining criteria for AKI regardless of KDIGO criteria. This is an important threshold
in the dosing package inserts for many beta-lactam antibiotics. As we have observed in
the current study, KDIGO class was less informative of a population of patients who would
be harmed by empiric dosage adjustments of the beta-lactam, antibiotics. We found no
difference in the rates of C. difficile infection, and rates of neurotoxicity were extremely
low. The concern for toxicity has been raised in several studies (Huwyler, Lenggenhager
et al. 2017) which may be a result of prolonged dosing rather than empiric dosage selection.
Our study has key limitations to be explored. The retrospective data collection
allows for selection bias on the treatment groups that is not readily obvious. Limiting our
cohort to bacteremia reduced the sample size of our study, and reduces external validityas many septic patients with AKI do not have concomitant bacteremia. The impact and
negative consequences of prematurely dosage adjusting in an AKI could extend to nonbacteremia populations, which has been seen in prior studies of UTI and intraabdominal
studies. (Solomkin, Hershberger et al. 2015, Wagenlehner, Umeh et al. 2015) There was
very low rates of toxicities, which is likely a result of missing information bias, inherent to
retrospective study designs. The selection of whom to dose adjust and whom not to, was
left up to the clinical care team. This strengthens our study design, as none of the
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participating sites had a protocol for dosage adjustments in the first 48h of therapy.
However, particular clinical information about each patient is impossible to determine who
would get a dosage adjustment, and who would not. It is likely that the sickest patients
were dose adjusted, as reflected in the higher mortality rates in this group.
Strengths of the study include the multi-center design, and selection of the sickest
patients who would plausibly be impacted by dose adjusting which increased internal
validity. Limiting the inclusion to bacteremia with susceptible MIC concentrations
minimized the impact of non-susceptible confounding. The groups were well balanced in
the unadjusted analysis, and applying regression modeling was successful in controlling for
measured confounders of the outcome.
In conclusion, the current study was able to demonstrate an association between shockfree survival in AKI patients (CrCl <50ml/min), without dosage adjustments of beta-lactam
therapy within the first 48h. This hypothesis should be tested in a prospective randomized
study to confirm these findings.

CHAPTER 3. AIM 2: TO EXAMINE THE RELATIONSHIP OF BETA-LACTAM
PK/PD TARGET ATTAINMENT ACHIEVEMENT, AS MEASURED BY
THERAPEUTIC DRUG MONITORING, WITH CLINICAL OUTCOMES IN
PATIENTS ADMITTED TO THE ICU FOR SEPSIS
3.1.1 Aim 2 Significance,
Rationale and Hypothesis
Aim 2: To examine the relationship of beta-lactam PK/PD target attainment achievement,
as measured by therapeutic drug monitoring, with clinical outcomes in patients admitted to
the ICU for sepsis
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Aim 2 Hypothesis: Achieving the beta-lactam PK/PD target attainment (100%T>4xMIC)
is associated with improved clinical outcomes in ICU patients with sepsis as compared to
those who fail to achieve the PK/PD target
3.1.2

Aim 2 Methods Impact of
Beta-lactam Target
Attainment on Outcomes of
Critically Ill Patients with
Sepsis: A Retrospective
Cohort Study

To test the hypothesis that beta-lactam trough concentrations are associated with
clinical outcomes, a retrospective cohort study was performed on adult patients, admitted
to the University of Kentucky Medical ICU from July 2017- December 2017. Patients were
included in the study if they received a beta-lactam antibiotic and therapeutic drug
monitoring during this time frame. Patients were excluded if they were incarcerated,
pregnant, or did not have beta-lactam concentrations available. At the time of the study,
beta-lactam TDM was non-protocolized and left to the treating healthcare team, however
when done, 2 levels were commonly drawn: a mid-dosing interval level, and a trough level.
This study was approved by the University of Kentucky institutional review board with a
waiver of informed consent.

Definitions and Outcomes
The primary outcome was PK/PD target attainment, defined as a trough
concentration of 100%T>4xMIC. The MIC threshold used in this study is 16 for
piperacillin/tazobactam and 2 for meropenem, both of which are the breakpoint,
respectively, for Pseudomonas aeruginosa. Secondary outcomes include 50%T>4xMIC,
and clinical cure as defined previously (Roberts, Paul et al. 2014) as completion of the
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antibiotic regimen without need for escalation or additional of antibiotics within 48h of
cessation. Mortality, ICU and hospital length of stay were also assessed. Creatinine
clearance was assessed with the Cockcroft-gault equation, and ARC was defined as a CrCl
of ≥130ml/min. (Cockcroft and Gault 1976, Sime, Udy et al. 2015)

Statistical Analysis
Continuous variables were tested for distribution by histogram visualization and
with the Shapiro-Wilk test. Continuous variables with normal distribution are presented as
mean (SD); otherwise are presented as median (IQR). Continuous variables were analyzed
using either the Student’s T-test or the Wilcoxon Rank-sum test as appropriate. Categorical
variables are presented as frequencies and proportions and analyzed using the Pearson’s
Chi-square or Fisher’s Exact test as appropriate. Statistical analyses were done using Stata
(version 14.2, Stata Corp, College Station, Texas, USA).
3.1.3

Aim 2 Results

A total of 43 patients were evaluated in this study, comprising 80 measurements.
The primary outcome was reached in 25/43 (58%) of patients, which then defined the two
cohorts (achieved the PK/PD goal, and did not achieve the PK/PD goal). The mean age
(SD) in years was 58 (17) vs 61 (15), in the not-achieved and achieved groups, respectively,
p=0.595. The majority of patients were male 75% vs 60%, p= 0.323 and white 94% vs
88%, p= 0.545, which did not differ between groups (PK/PD not achieved vs PK/PD
achieved respectively). Admission SOFA score was slightly higher in the PK/PD achieved
group 7.84 (4.11) vs 5.25 (3.8) as compared to the PK/PD not achieved group, however
this did not reach statistical difference in the bivariate analysis, p=0.51. Piperacillintazobactam was the most commonly monitored beta-lactam 41(95%), followed by
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meropenem 2(5%). Of the total 43 patients, 330 (82.5%) also met the secondary PK/PD
outcome of 50%T>4xMIC. Those achieving the PK/PD goal had a statistically
significantly lower CrCl than those not achieving the goal: 73ml/min (41-104) vs 109.5
ml/min (86.5- 146), and were more likely to be in shock 16(64%) vs 4 (25%), p=0.015.
Augmented renal clearance was more common in the PK/PD not achieved group, yet this
did not reach statistical significance: 6 (38%) vs 5(20%), p=0.217. Baseline characteristics
are displayed in Table 3.1.

Infection type, and treatment characteristics are summarized in Table 3.2. The type
of infection, use of concomitant aminoglycoside, total 24-hour dose of piperacillin received
at the time of TDM sampling, and use of extended interval dosing (infusion over 3+ hours)
was not different in the two groups. In those not achieving the PK/PD goal, the dose
required to achieve this goal exceeded the FDA labeling in 8/13 (62%).
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Table 3.1 Baseline characteristics by group, PK/PD not achieved and PK/PD achieved
Characteristic

N= 43

60 (15)

PK/PD not
achieved (n=16)
58 (17)

PK/PD achieved
(n=25)
61 (15)

Age

0.595

Gender (male)

28 (65%)

12 (75%)

15 (60%)

0.323

Race
White
AA

40 (93%)
3 (7%)

15 (94%)
1 (6%)

22 (88%)
3 (12%)

0.545

Weight

83.58 (25.18)

91.45 (22)

78.5 (26.16)

0.109

SOFA Score

6.9 (4.25)

5.25 (3.8)

7.84 (4.11)

0.051

Co-morbidities
Diabetes
Hypertension
CHF
Cirrhosis
CKD
COPD
Immunosuppressed
Other

13 (32%)
23 (56%)
8 (20%)
5 (12%)
3 (7%)
13 (32%)
22 (54%)
22 (54%)

7 (50%)
9 (64%)
2 (14%)
0 (0%)
0 (0%)
6 (43%)
9 (64%)
9 (64%)

6 (24%)
13 (52%)
6 (24%)
4 (16%)
3 (12%)
6 (24%)
12 (48%)
13 (52%)

0.098
0.458
0.471
0.114
0.177
0.221
0.957
0.458

Admission KDIGO
stage
0
1
2
3
Shock

22 (52%)
12 (28%)
5 (12%)
4 (9%)
20 (49%)

10 (63%)
5 (31%)
1 (6%)
0(0%)
4 (25%)

11 (44%)
6 (24%)
4 (16%)
4 (16%)
16 (64%)

0.244

0.015

2.2 (0.85)

2 (0.65)

2.32 (0.95)

0.256

94 (51-133)

109.5 (86.5- 146)

73 (41-104)

0.019

11 (27%)

6 (38%)

5 (20%)

0.217

7 (17%)

3 (19%)

4 (16%)

0.929

33 (82.5%)

9 (56%)

24 (100%)

0.001

Number of
nephrotoxins
CrCl at time of
TDM
ARC (CrCl
≥130ml/min)
ARC (CrCl
≥170ml/min)
50%T>4xMIC
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Table 3.2. Treatment characteristics
Characteristic

Infection type
Pneumonia
UTI
Other
Bacteremia
SSTI
Bone/joint
Intraabdominal
SBP/Medical
prophylaxis
Concomitant
aminoglycoside
Total daily dose
of piperacillin
Total daily dose
of meropenem

N= 43

PK/PD not
achieved (n=16)

PK/PD achieved
(n=25)

p
0.444

24 (58%)
4 (10%)
4 (10%)
2 (5%)
2 (5%)
2 (5%)
2 (5%)
1 (2%)

8(89%)
2 (12.5%)
2 (12.5%)
1 (6%)
2 (12.5%)
0 (0%)
0 (0%)
0 (0%)

15 (60%)
2 (8%)
2 (8%)
1 (4%)
0 (0%)
2 (8%)
2 (8%)
1 (4%)

12 (32%)

5 (33%)

7 (30%)

0.851

13.5 (13.5-13.5)

13.5 (13.5-18)

13.5(13.5-13.5)

0.056

6 (6-6)

-

6 (6-6)

NS

Extended
Infusion (3 or 4
hours)

30 (73%)

12 (75%)

18 (72%)

0.833

Gram negative
bacteria isolated
Bacteria
susceptible to
beta-lactam
MIC

12 (29%)

5 (32%)

7 (28%)

0.823

10/15 (67%)

5 (83%)

5 (56%)

0.264

8 (1-16)

5 (1-8)

6 (1.01- 16)

0.88

7 (30%)
6 (26%)
7 (30%)
3 (13%)

3 (33%)
3 (33%)
3 (33%)
0 (0%)

4 (29%)
3 (21%)
4 (29%)
3 (21%)

0.511

Type of bacteria
isolated
GNR
NF-GNR
Gram positive
Yeast

The clinical outcomes are summarized in Table 3.3. There was no difference in the
incidence of a positive clinical outcome in the two groups, 69% PK/PD not achieved vs
62% PK/PD achieved, p=0.666. Length of stay in the ICU, and the hospital were both
longer in the PK/PD achieved group. ICU length of stay 5(3.5-8) days in the PK/PD not
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achieved vs 11(7-15) day in those who achieved the PK/PD goal, p=0.009. Hospital length
of stay was 10(5-14.5) days in those who did not achieve the PK/PD goal, and 24(11-33)
in those who achieved, p=006. In-hospital mortality was similar in both groups, (21%),
p=0.965.
Table 3.3. Clinical outcomes
PK/PD achieved

N=43

PK/PD not
achieved
(n=16)

Positive clinical
outcome

24 (65%)

11 (69%)

13 (62%)

0.666

ICU Length of Stay

7.5 (4.512.5)

5 (3.5-8)

11 (7-15)

0.009

Hospital Length of
Stay

13.5 (8-27)

10 (5-14.5)

24 (11-33)

0.006

Mortality

9 (23%)

3 (21%)

5 (21%)

0.965

Clinical Outcome

Total

P-value

(n=25)

Population pharmacokinetic evaluations are found in Table 3.4. The elimination
coefficient (Ke) was higher and elimination half-life (T1/2) was shorter in the PK/PD not
achieved group, as compared to the PK/PD achieved group: (Ke) 0.34 (0.24- 0.51) vs 0.12
(0.07- 0.19), p <0.001, and T ½ 1.78 hours (1.37- 2.87) vs 5.77 hours (3.69- 9.53), p=
0.001, respectively. The Vd was similar between groups 27.29 L (11.51- 46.73) PK/PD not
achieved vs 26.22 L (21.5-39) PK/PD achieved, p= 0.545. However, the total body
clearance (Cl) was significantly higher in the PK/PD not achieved group: 8.38 L/hr (0.5710.41) vs 3.56 L/hr (2.7- 5.3), p<0.001. The median (IQR) Cmin in the PK/PD not
achieved group was 35.44(22.1- 44.52), as compared to the PK/PD achieved group: 110
(97-124), p <0.001. The Cmax was also lower in the PK/PD not achieved group: 125.46
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mg/L (96.16- 165.1) vs 188.59 mg/L (147.77- 293.29), p= 0.055. The Cmin and Cmax are
visually represented in Figure 3.1.

Table 3.4. Pharmacokinetic calculations
Characteristic

N= 43
0.19 (0.11-0.37)

PK/PD not achieved
(n=16)
0.34 (0.24- 0.51)

PK/PD achieved
(n=25)
0.12 (0.07- 0.19)

Ke

p

T½
Cmax

3.65 (1.9- 6.32)
161.85 (114-277.73)

1.78 (1.37- 2.87)
125.46 (96.16- 165.1)

Cmin

90 (31.5- 113)

35.44(22.1- 44.52)

5.77 (3.69- 9.53)
188.59 (147.77293.29)
110 (97-124)

Vd
Vd (L/kg)

26.22 (16.4-41.4)
0.38 (0.23-0.58)

27.29 (11.51- 46.73)
0.29 (0.14-0.53)

26.22 (21.5-39)
0.43 (0.28-0.71)

0.545
0.089

Cl (L/hr)

5.36 (2.85- 7.85)

8.38 (0.57- 10.41)

3.56 (2.7- 5.3)

<0.001

<0.001
0.001
0.055
<0.001

0

100

200

Concentration (mg/L)

300

400

Figure 3.1. Boxplot of Cmax, Cmin by group (PK/PD achieved and PK/PD not achieved)

PK/PD not achieved

PK/PD achieved

Cmax

73

Cmin

The correlation table of covariates and pharmacokinetic parameters (Volume and
Clearance) is found in Figure 3.2. Increasing age was not significantly correlated to
volume (correlation coefficient 0.18), or clearance (correlation coefficient -0.063).
Creatinine clearance had a low correlation to clearance (0.49), and negligible correlation
with volume (correlation coefficient 0.08). Weight highly correlates with volume
(correlation coefficient 0.82), and has negligible correlation to clearance (correlation
coefficient 0.22). A visual representation of observed vs predictions is found in Figure 3.3.
The majority of individual observations fall within the 90% prediction interval.
Figure 3.2. Covariate values of age, sex, CrCl plotted against population Volume and
Clearance
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Figure 3.3. Plot of individual predictions vs. observed values

Multivariate logistic regression
The results of the multivariate logistic regression model of PK/PD achieved are
found in Table 3.5. The original model started with the following variables: Serum
creatinine at TDM, Presence of shock, SOFA score, gender, age, weight, ARC, history of
diabetes, AKI at admission. Controlling for other variables in the model, for every point
increase in serum creatinine at the time of TDM, the odds of achieving the PK/PD goal
increased by 3.83- fold [OR 3.83, (95% CI 1.298, 11.2960), p=0.015]. Controlling for other
variables in the model, the presence of shock at the time of TDM increased the odds of
PK/PD achieved by 11.81- fold [OR 11.81, (05% CI 1.806, 77.29), p=0.010]. A past
medical history of diabetes was associated with an 87% decreased chance of achieving the
PK/PD goal, [OR 0.13, (95% CI 0.018, 0.940), p=0.043].
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Table 3.5. Multivariate logistic regression model of predictors of PK/PD achieved
PK/PD Achieved

Odds Ratio

P>|z|

[95% Confidence Interval]

Serum Creatine at TDM

3.83

0.015

1.298, 11.296

Shock (Y/N)

11.81

0.010

1.806, 77.29

History of diabetes

0.13

0.043

0.018, 0.940

39 observations
Model p <0.001
R2 0.34
VIF 1.02
Hosmer-Lemeshow goodness of fit test p=0.396
Breusch-Pagan / Cook-Weisberg test for heteroskedasticity p= 0.0076
Final model adjusted for Robust Standard Errors

A multivariate logistic regression model was built with the same initial variables,
also including PK/PD goal achieved. The results are summarized in Table 3.6. Controlling
for other variables in the model, admission SOFA score and male gender were the only
variables significantly associated with a positive clinical outcome. For every 1- unit
increase in admission SOFA score, the odds of achieving a positive clinical outcome
decreased by 47% [OR 0.53, (95% CI 0.331, 0.855), p=0.009]. Male gender was associated
with a 94% decrease in a positive clinical outcome [OR 0.06, (95% CI 0.005, 0.889),
p=0.040].
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Table 3.6. Multivariate logistic regression model of predictors of a good clinical outcome
Good clinical outcome

Odds Ratio

[95% Confidence Interval]

P>|z|

SOFA score

0.53

0.009

0.331, 0.855

Male gender

0.06

0.040

0.005, 0.889

Shock

16.59

0.075

0.756, 364.14

35 observations
Model p <0.001
R2 0.37
VIF 1.02
Hosmer-Lemeshow goodness of fit test p=0.594
Breusch-Pagan / Cook-Weisberg test for heteroskedasticity p= 0.172

3.1.4 Aim 2 Discussion and
Conclusion
In this small retrospective cohort study of septic patients receiving beta-lactam
antibiotics, goal PK/PD target attainment was achieved by roughly 2/3 of patients (58%).
Target attainment was not associated with a positive outcome in this cohort, however it
was associated with a longer hospital and ICU length of stay. This finding is likely due to
the overall sicker population represented in those who achieved PK/PD target attainment
(the higher baseline SOFA score and higher proportion of patients with shock, and lower
CrCl).
The overall target attainment of 58% is higher than expected, as compared to prior
reports published in the literature. In a large point prevalence study (DALI) of beta-lactam
TDM in the ICU, the aggressive PK/PD target of 100%T>4xMIC was reached by only
35 % of patients. (Roberts, Paul et al. 2014) Another prospective study of 18 critically ill
patients published this target attainment reached 10-20% of the time. (Kaska, Havel et al.
2018) Another study evaluating TDM of meropenem in patients with KPC-producing
Klebsiella pneumoniae infections reported that only 50% of cases reached the target
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attainment of 100%T>4xMIC, which was the target in our study. (Pea, Della Siega et al.
2017) Overall, the ability of standard dosing of beta-lactams to reach this PK/PD target is
consistently poor. Factors associated with not reaching this goal are the presence of ARC,
younger age, volume status, and intermittent bolus dosing regimens. (Carrie, Legeron et al.
2018, Carrie, Petit et al. 2018, Kaska, Havel et al. 2018) In our study, we determined
increasing serum creatinine and a presence of shock to be positively associated with
achieving the PK/PD goal. A past medical history of diabetes, however, was significantly
associated with not achieving the PK/PD goal. Increasing serum creatinine can reflect
impaired GFR is a common finding throughout the literature, however the diagnosis of
shock is a more difficult finding to explain in this study, and may represent unmeasured
confounding. The role of diabetes in predicting target attainment, outside of a disease
severity assessment tool, is unclear and also likely represents statistical noise in this small
cohort.
Achieving the PK/PD goal in this study was not associated with a positive outcome.
This is dissimilar to the finding of the DALI study, and others which have demonstrated a
clinical outcome benefit to achieving this aggressive PK/PD goal. (Roberts, Paul et al.
2014) (Carrie, Petit et al. 2018) This discrepant finding could be attributed to multiple
factors. Our patients had documented infection in fewer than 30% of cases. This present
cohort also received a high proportion of empiric aminoglycoside double coverage therapy.
The rationale behind empiric dual gram-negative therapy is to provide coverage for
possible resistant organisms, and to augment bactericidal killing, however the benefit of
this practice remains controversial. (Kumar, Safdar et al. 2010)
Strengths of the current study include the empiric dosing and infusion strategy of
the beta-lactams. Piperacillin was most commonly dosed at 3.375 grams every 6 hours, and
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infused over 3 hours in >70% patients in both groups, despite apparent CrCl. Both
meropenem patients received the highest dose, with extended infusion interval. These
homogenous dosing regimens minimized a treatment effect with the smaller chance of
reaching target attainment with intermittent infusion regimens. Complete, 2 level TDM
data were available for the majority of patients, allowing for a robust pharmacokinetic
assessment.
The most important limitation of this study is the analytic method used to detect the
beta-lactam concentrations. The bioactivity assay method of detection utilizes a bacterial
probe to determine the antibiotic concentration based on the zone of inhibition. This
method can have high intra-rater reliability, but is subject to interfering substances which
can contaminate the sample, augmenting the killing effect. (Shaw 1979) One study
evaluated ciprofloxacin concentrations measured by HPLC or bioassay in serum and urine.
The serum measurements were comparable; regression slope difference 1.0 (99.9%
confidence limits: 0.984 <slope < 1.035). However, in urine the bioassay overestimated the
antibiotic concentration 30.2 +/- 8.5 HPLC vs 38.2 +/- 5.9 bioactivity assay. Slope
difference was 1.327 < slope < 1.698. (Joos, Ledergerber et al. 1985) Another study
compared ciprofloxacin concentrations in serum by HPLC or bioactivity assay, and found
a similar finding. The microbiologic assay reported higher concentrations than HPLC,
owed to detection of active metabolites according to the authors. (Khan, Khan et al. 2012)
The presence of concomitant antibiotics with similar bioactivity could have falsely elevated
the beta-lactam concentrations in our study, which would explain the higher proportion of
target attainment achieved.
In conclusion, at standard doses, target attainment was low at 58% in this study.
Use of a bioactivity assay method of detection may overinflate the concentration result.
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Prospective studies of higher dosage regimens should be done to achieve a higher
proportion of target attainment, and a chromatographic analytic method should be
considered. Set the stage for renal biomarkers in the next session.

CHAPTER 4. AIM 3: TO DEVELOP A LABORATORY DEVELOPED TEST USING
LC-MS
TO
MEASURE
BETA-LACTAM
CONCENTRATIONS
IN
HOSPITALIZED PATIENTS

4.1.1 Aim 3 Significance,
Rationale and Hypothesis
Laboratory developed tests (LDT) are an important tool to aid in patient care for the
clinician. In the absence of an FDA approved test, the LDT is developed internally,
validated, maintained by the institution, and used for in-house patient care. (Genzen 2019)
For example, all beta-lactam assays are considered an LDT. The LDT is regulated by the
Centers for Medicare and Medicaid, and abide by all Clinical Laboratory Improvements
Amendments (CLIA) regulations. The requirements of laboratory developed test include
a laboratory director with a MD or PhD with specific board certification. The test must be
approved with proper validation, ongoing performance assessments, and provide
interpretations to the ordering physicians. Laboratory developed tests are commonly seen
in settings where commercial tests are unavailable to meet a clinical need, including new
drug monitoring, or advanced genetic testing. The landscape of federal regulation over
laboratory developed test has begun to change over the years, with the FDA desiring more
regulatory control over these tests. (Genzen 2019) Therefore, to meet the needs of the
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patients at UKHC, an LDT for beta-lactam assay measurements will be developed and
implemented into clinical practice.
Overall Aim 3: To develop a Laboratory Developed Test using LC-MS to measure betalactam concentrations in hospitalized patients
Aim 3 Hypothesis: A Laboratory Developed Test utilizing LC-MS technology will
improve beta-lactam concentration accuracy over available detection methods, and
facilitate personalized dosing of beta-lactam antibiotics for UKHC hospitalized patients
with sepsis
4.1.2

Aim 3: Methods

4.1.2.1 Background and Rationale for a Laboratory Developed
beta-lactam assay
The Clinical and Laboratory Standards Institute (CLSI) regulates laboratory
developed tests, including beta-lactam assays. (CLSI 2014) CLSI provides guidance for
development of liquid chromatography-mass spectrometry (LC-MS) methods for
laboratory developed test. Mass spectronomy measures the size of a compound, therefore
allowing for identification and quantification. LC-MS is advantageous over traditional gas
chromatography (GC-MS) for several reasons, including a wider range of molecular
weights able to measure, with lower limits of detection. Cleaning the ion source is easier
and requires fewer parts, and the run times are generally shorter. While the clinical lab will
employ multiple testing platforms, the LC-MS is optimal for beta-lactam measuring.
Pitfalls of the LC-MS method includes requiring advanced technician training with special
technical skills. The throughput can be limited in number, as compared to the immunoassay
method, and LC-MS comes with high instrumentation costs. The CLSI has set forth
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guidance in the EP19 document for development and validation of a laboratory developed
test. (CLSI 2014) This process includes two overarching themes with specific steps in
each: Establishment and Implementation, depicted in Figure 4.1.
Figure 4.1 Testing Lifecycle

Step 1. Feasibility and design assess use of the test, patient population, clinical
demand and volume. This includes consultation with clinicians on how the test will be used
through a literature review and marketing assessment of the center. Essentially, there must
be a clinical need and the ability of the laboratory to meet the need, as well as a way to
bill/pay for the test.
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Step 2. Development assess the materials needed and technical features required to
establish the test. Development uses CLSI method evaluation standard (EP), and determine
precise requirements of the test. Each batch of reagent requires manufacturing records. The
end of the development phase, is the design output. This is a test that will work, prior to
validation.
Step 3. Validation is defined as the ‘Objective evidence that the requirements for a
specific use or application of the test have been fulfilled’. (CLSI 2014) Validation confirms
the final test is suitable for the measurement, the population and in the specific condition.
The steps of validation include: precision, accuracy (measurement against a gold standard),
measuring interval, reference interval (normal range), sensitivity, limit of detection/
detection capacity, analytical specificity (identification of interfering substances), clinical
validation (testing in the target population works), reagent and sample stability (storage
conditions of plasma/serum), and risk assessment. These steps essentially inform the
package insert, if the test were to be commercially available.
Step 4: Preliminary evaluation includes a small batch testing to confirm the
calibration and quality control is working. This is a step to ensure the test performance is
satisfactory.
Step 5: Verification is objective criteria that the test performs in the way the
manufacturer (or internal laboratory) claims. Specifically, it is the evidence that the specific
requirements are completed. Verification includes optimal performance in a variety of
settings: different operators, equipment changes, room changes, space configuration
changes, storage conditions (ex: -20c or -80c freezer) and in different patient populations.
Verification should be done by a laboratory in which the similar patient conditions are met,
a CLIA laboratory, not a research laboratory if the test is to be done for patient care.
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Step 6: Launch is the transition of the test into patient care. This step includes training
of end users, clinicians who will order the test. Streamlining education of staff, and
incorporation of informatics and IT for test ordering.
Step 7: Maintenance phase describes the phase of normal clinical use. Ongoing
quality assurance and quality control, evaluate of precision, accuracy, results review and
follow-up. This step is the same as a commercially available test, and does not differentiate
between the origin.
Step 8: Retirement is the sunsetting of the test, which includes maintaining document
control and records of the test. Test retirement can occur for any reason, mostly due to
advances in technology and replacement with a newer more advanced test.

4.1.2.2 Beta-Lactam Measurements by Liquid
Chromotagraphy/ Tandem Mass Spectromonony: A
Laboratory Developed Test
The following outline our steps for the successful development of a novel LCMS/MS method for determining concentrations of cefepime, meropenem and piperacillin
in human blood. Drug reagent standards were obtained from Sigma-Aldrich in the forms:
Piperacillin Monohydrate USP Reference Standard, Meropenem USP Reference Standard,
Cefepime Hydrochloride USP Reference Standard. Additional reagents for liquid
chromatography (LC) including HPLC grade acetonitrile and methanol were also obtained
from Sigma Aldrich. Internal standard material in the form of the deuterated beta lactam
drugs including piperacillin-d5, meropenem-d6 and cefepime-d3 sulfate (Table 4.1) were
obtained from Toronto Research Chemicals.
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Table 4.1. Standards used for beta lactam method development
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The beta lactam method at the University of Kentucky Clinical laboratory was
developed on a Sciex 6500 LC-MS/MS platform. Identification of the beta lactam
antibiotics for this study by mass spectrometry was first achieved by finding the appropriate
MS parameters to identify unique qualifier (Q1)/quantifier (Q3) ion pairs for each of the
standard materials and the respective internal standards. Piperacillin and meropenem
yielded optimal fragmentation patterns in negative ion mode with a Q1/Q3 (Da) of 516/330
or 516/232.9 and 382/311.1 or 382/267, for piperacillin and meropenem, respectively.
Importantly, the deuterated internal standard material did not reveal a unique fragmentation
pattern between the non-deuterated USP standard and the deuterated IS, therefore, the
meropenem-d6 was adopted as the internal standard for both piperacillin and meropenem
with an internal standard Q1/Q3 of 388/317.1 Fragmentation and identification of cefepime
was optimal in positive ion mode with a Q1/Q3 of 481.4/396.2 or 481.4/86.1 with the
cefepime-d3 Q1/Q3 established at 484.2/89.3. Instrument parameters were set to switch
polarization modes to accommodate the detection of all three beta lactams within the same
run. In addition, the final method was established using a scheduled MRM scan type with
the Q1/Q3 ion pairs identified above. The LC methodology was developed and optimized
on a Kinetex 2.6 µm reverse phase C18 100 Å Phenomenex column with the dimensions
of 150 x 4.6 mm. The LC method optimized with a flow rate of 0.4 mL/min and a linear
solvent gradient of water to 50:50 MeOH to MeCN from 5%-90% for a total method
duration of 7 minutes, including a re-equilibration phase to prepare the column for
subsequent injections. LC-MS/MS chromatography traces for the completed method
demonstrating optimized conditions and peak resolution are shown in Figure 4.2.
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Figure 4.2. LC-MS/MS chromatography traces from the beta lactam method development
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The optimized sample preparation protocol for serum specimens includes an
extraction/protein precipitation step with a 100% acetonitrile solvent solution with rigorous
vortexing, followed by centrifugation. The resulting supernatant is removed from the
centrifuged sample and dried down with dry air using a standard hood manifold. Following
this step, the residual sample is reconstituted in LC mobile phase consisting of 0.1% formic
acid in distilled water, prior to injection into the LC-MS/MS instrument. The complete
beta-lactam method was calibrated using commercially available standards from
Chromsystems diagnostics.

4.1.2.3 Aim 3 Results
Clinical Method Validation
Method validation for a laboratory developed test that will be used in patient care
involves a number of steps to assess the analytical performance of the assay. In brief, the
studies necessary to complete a laboratory developed test include, determining the limit of
quantification (LOQ), simple and complex precision to assess the random error of the
assay, accuracy and linearity to examine the performance of the assay over the desired
analytical measuring range of the assay, comparison studies to a reference laboratory or
method to assess the relative performance of the assay and identify any biases that would
contribute the systematic error of the assay, interference studies and stability studies to
determine the optimal handling and storage conditions for clinical samples. The calibration
curve for our method validation is found in Figure 4.3.
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Figure 4.3. Calibration Curve
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Acquisition and Laboratory Processing of Patient Blood Specimens for Clinical
Method Validation Experiments
The University of Kentucky Clinical Laboratory has policies and procedures to
follow when handling human samples for research. In conjunction with the Enterprise Preanalytic coordinator, a process was established to receive human samples, and process
them in the Clinical lab for the beta-lactam study. Institutional review board (IRB) approval
was obtained for this study. Enrollment criteria for patient eligibility for the validation arm
of the study included 1) ≥ 18 years old, non-pregnant, non-incarcerated with admission to
a non-COVID MICU 2) diagnosis of sepsis and being treated with a beta-lactam of interest
(cefepime, meropenem, piperacillin). Patients were excluded if they 1) Comfort care
decision to limit support or imminent death, as decided by MICU team or withdrawal of
MICU care by family within 72h of enrollment 2) Planned antibiotic duration <48 hours
(surgical or medical prophylaxis) 3) acute kidney injury on admission, defined as a KDIGO
Stage 1 or higher.

The procedure for handling samples is outlined below, and in Figure 4.4 Processing
Request Form.

Using the Processing Request Form
1.

Collect 1 red top from patient, labeled with the subject ID and sample ID as the two
patient identifiers.
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2.

Send red top labeled with the two patient identifiers and a copy of the BETALAC
Processing request form with matching identifiers to the lab.

3.

The lab will then order the processing charge with this information.

4.

The lab will then centrifuge the red top and make three aliquots to store at -70⁰C
until picked up by Dr. Schuler or the designated special chemistry staff for sample
analysis.
a.

Aliquot 1: ARUP aliquot requiring sterile processing

b.

Aliquot 2: Aliquot for Florida

c.

Aliquot 3: Aliquot for– special chemistry in-house testing

For a select number of initial blood draws, 5 aliquots will be done. The additional
specimens will be used for an internal comparison study between green (Li-heparin) and
red top (Serum-no additive) tubes. This comparison study is to facilitate the transition to
patient care, where the commonest labs drawn, “AM labs” are in a green top tube, thus
negating the need for drawing additional blood specimens from our patients. With the
transition to green top tubes, clinical pharmacists and providers will be able to place an
‘add on order’ to AM labs, for a beta-lactam level. Acceptance of this proposed work-flow
is pending the final stability and comparison results, as the results of these studies will
dictate how long a sample can remain at room temperature, and still be eligible for a betalactam level ‘add-on’.
To facilitate the patient comparison studies with reference laboratories, contracts
and billing accounts were created with the University of Florida (UF) and ARUP
Laboratories. A two-way comparison study will be done with ARUP laboratory, and the
91

University of Florida Infectious Disease Pharmacokinetics Laboratory. A total of 40
samples will be sent to ARUP and 40 samples will be sent to University of Florida
Infectious Disease Pharmacokinetics Laboratory representing the identical time points for
each of the unique patient samples to complete the comparison studies. The University of
Florida Infectious Disease Pharmacokinetics Laboratory will serve as the reference
laboratory for our method validation. Their laboratory utilizes a LC-MS/MS method for
beta-lactam detection, and is a CLIA certified, College of American Pathologists (CAP)
accredited laboratory for patient care. The UF laboratory specifications for sample
handling are for the blood (0.5ml) to be drawn in a red top tube, avoiding a gel separator.
After the blood clots, centrifuge the samples, and freeze at -70°C. Use a different tube for
each test and time of collection, and label the tubes with the patient's name, date and time
of collection, and the drug(s) to be assayed. Samples should be packed in dry ice, and sent
to the laboratory with the requisition form via overnight delivery Monday through Friday.
The listed stability from UF is 1 year at -80°C. Results will be available via fax within 48
hours.
A second reference laboratory comparison to the ARUP bioactivity method will
also be performed. ARUP is a CLIA certified, CAP accredited reference laboratory. The
analytic method for beta-lactams is the bioactivity assay. Specific handling instructions
include: draw 2 ml of serum (1ml minimum), centrifuge at ambient temperature, and
process into a sterile container. This will minimize the risk of interfering substances. The
sample should be frozen at -70°C, and shipped on dry ice to ARUP within 7 days, according
to their internal stability. Since the bioactivity assay uses a bacterial probe and zone of
inhibition to measure the concentration, the requisition form must contain concomitant
antibiotics the patient is receiving.
92

Figure 4.4. Processing request form
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4.1.3

Aim 3 Discussion and
Conclusion

We were able to develop and validate a LC-MS based beta-lactam assay as a
Laboratory Developed Test for the University of Kentucky. The specimen stability and
comparison studies are currently underway. A patient care protocol for use at the
University of Kentucky, and education plan for providers and front-end users of the test is
underway.
CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS
5.1.1

Conclusions and Future
Directions

In conclusion, through an extensive review of the literature, we were able to
demonstrate a significant gap in the science of understanding of beta-lactam dosing in
critically ill patients with sepsis, and the optimal methods of measuring beta-lactam
concentrations. We demonstrated, by accomplishing Aim 1, the current practice of
following FDA renal function labeling for beta-lactam dosing in septic patients with AKI
is associated with poorer outcomes. In accomplishing Aim 2, we confirmed that optimal
beta-lactam target attainment is inconsistently achieved in septic patients. However, we
recognize the significant and important limitation of the sampling methods done in this
study, which greatly interferes with the interpretation of the concentrations, therefore
restricting the generalizability of this study. By accomplishing Aim 3, we were able to
advance the science of understanding of beta-lactam dosing by funding a Laboratory
Developed Test to be developed and used in clinical practice at the University of Kentucky.
The future directions of this work include to validate the laboratory developed test, and
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perform a prospective trial testing these hypotheses prospectively. The role and
implications of protein binding alterations of beta-lactam antibiotics should be explored in
future studies of pharmacokinetic evaluations in critically ill patients.
The next steps for this area of research would be a prospective randomized
controlled trial. To overcome the important confounder of dual empiric coverage of gramnegative infections, we would randomize to double coverage with an aminoglycoside vs.
no aminoglycoside. Participants would be randomized into 4 groups, 1) beta-lactam TDM
plus concomitant aminoglycosides, 2) standard beta-lactam dosing plus concomitant
aminoglycosides, 3) beta-lactam TDM with no aminoglycoside and 4) standard betalactam dosing and no concomitant aminoglycoside. There is clinical equipoise with the
practice of prescribing empiric aminoglycosides, and this study design could also help
answer the role of this practice. To overcome ethical considerations of provider preference,
providers could decline entry into the study, should they feel strongly about prescribing an
aminoglycoside. The TDM targets in the study should be the more aggressive target of
100%t>4xMIC. Clinical outcomes would include microbiologic cure, mortality, ICU and
hospital LOS. With the aminoglycoside arm of the study, a robust analysis on
nephrotoxicity risk of this practice could be evaluated as well.
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Thompson Bastin ML, Berger K, Adams CA, Altschuler J, Dixit D, Effendi MK,
Heavner MS, Johnston JP, Lemieux DG, Lemieux SM, Littlefield AJ, Owusu KA, Rose
C, Rouse GE, Hammond DA. Adapting Clinical Pharmacy Staffing Models During the
COVID-19 Pandemic: Lessons Learned and Considerations for Future Disaster Planning.
ACCP Annual meeting 2020
Thompson Bastin ML, Zhu M, McCleary E. Risk factors for diabetic ketoacidosis
treatment failure in medically critically ill patients. Critical Care Medicine
2020;48(1):141
Bissell B, Laine M, Thompson-Bastin M, Flannery A, Kelly A, Neyra J, Morris P.
Protocolized Diuresis-Guided Volume De-Resuscitation in the Intensive Care Unit.
Critical Care Medicine 2020;48(1):679
Kelley J, Bissell B, Thompson-Bastin M, Flannery A. Renal Effects of Vasopressin on
Cirrhotic Patients With Septic Shock. Critical Care Medicine 2020;48(1):680
Caroline E Hauschild, Eloy Ruiz, Melissa L. Thompson Bastin, Kirby Mayer, Brandi
Adams, Lisa Fryman, Monica Talbott, Javier A Neyra. Development and implementation
of a quality management program for continuous renal replacement therapy deliverables.
Advances in Critical Care Nephrology 2020
Thompson Bastin ML, Nerusu S, Adams P, Morris P and Neyra JA. Phosphoruscontaining Solutions Reduce Incident Hypophosphatemia and Associate with Better
Outcomes in Critically Ill Patients Requiring Continuous Renal Replacement Therapy.
American Journal of Respiratory and Critical Care Medicine 2019;199:A5994
Srinadh A, Flannery A, Kelly A, Bhattacharya D, Thompson Bastin ML, Nepal C,
Cassity E, Gopinath A, Morris R. Pain Assessment and Sedation Delivery in
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Mechanically Ventilated Patients: Can We Do It Better? Critical Care Medicine
2019;47(1):547
Bissell B, Flannery A, Pandya K and Thompson Bastin ML. Comparison of Sodium
Acetate Buffering Capacity in Critically Ill Patients with and without Cirrhosis. ACCP
Global Conference, Seattle, WA. Poster presentation at ACCP Global Conference on
Clinical Pharmacy. [Oct 2018]
Wong A, Smith Z, Thompson Bastin ML, DeMott JM, Gross K, Bissell B, Heavner M,
Droege M, Hohlfelder B. Development of pharmacy residency research resources within
the Critical Care PRN. ACCP Global Conference, Seattle, WA. Poster presentation at
ACCP Global Conference on Clinical Pharmacy. [Oct 2018]
Thompson Bastin ML, Short T, Cook A, Rust K, Flannery A. Perceptions of TelevisionBased Education in the ICU: A Comparison between Patients and Care Providers.
Critical Care Medicine 2018; 46(1):176
Dave K, Thompson Bastin ML, Flannery AH, Cassity E, Kelley A, Morris P. Evaluation
of Stress Ulcer Prophylaxis Indications at a Large Academic Medical Center. Critical
Care Medicine 2018; 46(1):507
Thompson Bastin ML, Soper MK, Laine ME, Dhar S. Propylene Glycol Toxicity from
Pentobarbital Infusion in Refractory Status Epilepticus. Critical Care Medicine
2018;46(1):455
Bissell B, Magee C, Thompson Bastin ML and Flannery A. Detrimental Effect of
Supplemental Dextrose Infusions In The Intensive Care Unit. Critical Care Medicine.
2018; 46(1):200
Magee C, Thompson Bastin ML, Laine M, Bissell B, Moran P, Owen G, Morris P and
Flannery AH. Insidious Harm of Medication Diluents As A Contributor To Cumulative
Volume And Hyperchloremia. Critical Care Medicine 2018;46(1):6
* Abstract received a Star Research Award (top 10 submissions)
Laine M, Moody B, Flannery AH, Kalema A and Thompson Bastin ML. Need for
expanded candida score for empiric antifungal use in medical critically ill patients?
Critical Care Medicine 2018;46(1):323
Ali D, Clark J, Flannery AH, Kelly A, Oyler D, Thompson Bastin ML. De-Escalation
of Dexmedetomidine-Based Sedation Utilizing Clonidine in Medical and Surgery ICU.
Critical Care Medicine 2018;46(1):489
Flannery AH, Bissell B, Owen G, Moran P, Kelly A, Thompson Bastin ML. Assessing
the Impact of Albumin Use on Vasopressor Duration And Mortality In Septic Shock.
Critical Care Medicine 2018;46(1):687
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Woolum, Jordan; Thompson Bastin ML, Kelley A, Flannery AH. Association of
Thiamine Administration with Outcomes in Septic Shock Patients. Critical Care
Medicine 2018;46(1):711
Fu SH, Flannery AH, Thompson Bastin ML. Acute Hepatotoxicity after High-Dose
Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report 2017
ACCP Meeting
Flannery AH, Thompson Bastin ML, Fu S, Bissell BD, Morris PE and Neyra J.
Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury
in critically ill adults: a systematic review and meta-analysis" 2017 ACCP Annual
Meeting
Bissell BD, Flannery AH, Adkins DA, Thompson Bastin ML. Safe, Efficacious and
Aggressive Treatment of Life-Threatening Hypophosphatemia During Recovery from
Acute Fulminant Hepatic Failure. American Journal of Respiratory and Critical Care
Medicine 2017;195:A3835
Bissell BD, Magee C, Thompson Bastin ML, Moran PR, Flynn JD, Flannery AH.
Hemodynamic Instability Following Vasopressin Withdrawal in Septic Shock. American
Journal of Respiratory and Critical Care Medicine 2017;195:A5767
Thompson Bastin ML, Flannery AH, Montgomery-Yates AA, Smith KH, Hook C,
Cassity EP, Eaton PM and Morris PE. ICU "Hotel Rounds" as a Quality Improvement
Tool: Changing Practice in a Medical Intensive Care Unit. Critical Care Medicine
2016;44;108
Thompson Bastin ML, McLaughlin CP, Turner B, Williams MV and Li, J. Development
of an ICU-Based Pharmacy Technician to Improve the Medication Distribution Process.
Critical Care Medicine 2016;44:95
* Abstract received a Star Research Award (top 10 submissions)
Thompson Bastin ML, Cook AM and Flannery AH. Simulation Training to Prepare
Pharmacy Residents for High-stress, High-impact Clinical Scenarios. Critical Care
Medicine 2016;44(12)181
Thompson Bastin ML, Curlin A and Flannery AH. Angioedema from Combination
Sitagliptin and Lisinopril in a Diabetic Patient. Critical Care Medicine 2016;44(12)542
Thompson Bastin ML, Neville NR, Parsons RE, Flannery AH, Tennant SJ, and Johnson
CA. An Unusual Case of Salmonella Causing Pneumonia and Septic Shock in an
Immunocompetent Patient. Critical Care Medicine 2016;44(12):524
La M, Thompson Bastin ML, Gisewhite J and Flannery AH. Impact of Restarting Home
Neuropsychiatric Medications on Sedation Outcomes in Medical ICU Patients. Critical
Care Medicine 2016;44(12)333
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Magee C, Thompson Bastin ML, Burgess D, Nestor M and Cook AM. Effects of Fever
burden and increased use of antibiotics in patients with Subarachnoid Hemorrhage.
Critical Care Medicine 2016;44(12):262
Thompson Bastin ML, Gokun Y, Macaulay TE, Clifford T. Use of Fenoldopam in
Calcineurin Inhibitor Induced Nephrotoxicity. Critical Care Medicine 2013;41(12)
* Abstract nominated as a Research Citation Finalist
Noel Z, Bastin MT, Montgomery-Yates A, Flannery A. Comparison of high dose
versus standard dose oseltamivir in critically ill patients with influenza. Critical Care
Medicine 2015;43(12):114-115
May CC, Arora S, Parli SE, Thompson Bastin MT, Cook AM. Levetiracetam
pharmacokinetics in subarachnoid hemorrhage patients with augmented renal clearance: a
Monte Carlo Simulation. Pharmacotherapy 2014: 34
Thompson Bastin ML, Fugit A, Martin C. Challenges Associated With and Ways to
Improve the Transition from Resident to Preceptor: A Pilot Study. Poster presented at
the American Society of Health-System Pharmacists National Preceptors Conference
May 2013. Washington, DC
Thompson ML, Weant K, Baker S. Effect of Etomidate on Adrenocortical
Suppression: A Review of Intubated Septic Patients. Poster presented at the Society of
Critical Care Medicine 41st Congress. February 2012. Houston, Tx
Thompson ML, Boan A, Blue AV. Knowledge and Attitude Changes of Health
Profession Students Towards Pharmacy: Before and After Completion of an
Interprofessional Education Fellowship. Poster presented at American College of
Clinical Pharmacy Annual Conference October 2010. Austin, Tx

BOOK CHAPTERS
Cook AM and Thompson Bastin ML. “TDM of anti-infectives” in PK/PD in
Special Populations and Prophylaxis, Infectious Disease Pharmacotherapy SelfAssessment Program, 2019; Marc Scheetz, editor.
Thompson Bastin ML and Bissell BD. “Corticotrophins, corticosteroids, and
prostaglandins” in Side Effect of Drugs Volume 41, 2018; Sidhartha D. Ray, editor
Trobaugh KA, Flannery AH and Thompson Bastin ML. “Special Populations:
Critical Care and Transplantation” in Demystifying Drug Dosing in Renal
Dysfunction; Brandon Nemecek and Drayton Hammond, editors: American Society
of Health-System Pharmacists, Bethesda, MD.
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“Cardiovascular Critical Care” in ACCP Critical Care Prep and Review Course.
Chapter reviewer. 2018- Present

SELECTED PRESENTATIONS
NATIONAL/STATE/REGIONAL

IRB Overview
August 2020
Preceptor’s Playbook: Tactics, Techniques, and Strategies
American Society of Health-System Pharmacists
Publications and Presentations
August 2020
Preceptor’s Playbook: Tactics, Techniques, and Strategies
American Society of Health-System Pharmacists
Research and Publication Opportunities for Students
August 2020
Preceptor’s Playbook: Tactics, Techniques, and Strategies
American Society of Health-System Pharmacists
Pharmacy Implications of CRRT
August 2020
Baxter Healthcare webinar/training
Optimization of Beta-lactam Dosing in Critically Ill Patients: Ready for Prime Time?
March 2020
Kentucky Society of Health-System Pharmacists Spring meeting
Lexington, KY
Renal Replacement Therapy in the ICU: What Every Intensivist Should Know
October 2019
American College of Chest Physicians. CHEST Annual Meeting
New Orleans, LA
Solutions in CRRT
October 2019
Acute Therapies Summit, sponsored by Baxter Healthcare.
New York, NY
Antibiotic Dosing Concepts in CRRT
October 2019
Acute Therapies Summit
New York, NY
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Overcoming Challenges of Medication Dosing in CRRT
October 2019
Baxter Healthcare Webinar series
Solutions in CRRT
November 2018
Acute Therapies Summit
Louisville, KY
Medication Dosing in CRRT
November 2018
Acute Therapies Summit
Louisville, KY
Role of ionized magnesium in the care of the ICU patient:
July 2018
implications for point of care, pharmacy utilization and clinical outcomes.
NOVA Biomedical Webinar series
Development of an ICU-based Specialty Technician to Improve the
October 2018 Medication Distribution Process.
Kentucky Society of Health-System Pharmacists Fall meeting
Lexington, KY
Sepsis: Treatment Considerations and Case Review
October 2016
Highlands Regional Sepsis Summit
Prestonsburg, KY
What is the Future of Epinephrine in Cardiac Arrest?: Pros and Cons
June 2015
American Heart Association Strive to Revive Symposium
Lexington KY
Ketamine: A review of the Contemporary Uses of an Old Medication
October 2013
Kentucky Society of Health-System Pharmacist Fall meeting
Indiana
Effect of Etomidate on Adrenocortical Suppression:
April 2011
A Review of Intubated Septic Patient
Great Lakes Residency Conference
West Lafayette IN.
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Management of Atrial Fibrillation in the Intensive Care Unit
October 2011
University of Kentucky College of Pharmacy Grand Rounds
Lexington, KY
Developing Contemporary Pharmacy Practitioners Through
April 2011 Interprofessional Education.
University of Kentucky College of Pharmacy Grand Rounds
Lexington, KY
LOCAL
Pharmacotherapy of Pain, Agitation and Sedation in the ICU
July 2014- 2017
University of Kentucky Pulmonary/Critical Care Fellows Noon Conference
Airway Pharmacology: Review of Medications used in RSI.
July 2014- 2017
University of Kentucky Pulmonary/Critical Care Fellows Noon Conference
Pharmacotherapy of Sepsis Treatment in the MICU.
2014- 2016

University of Kentucky Pulmonary/Critical Care medical intensive care unit nursing staff

Pharmacotherapy of Sedation in the MICU
2014- 2016
University of Kentucky Pulmonary/Critical Care medical intensive care unit nursing staff
Sepsis
October 2013
University of Kentucky pharmacy department.
Acute Alcoholic Hepatitis
October 2013
UK HealthCare Pharmacy Residency program
Interprofessional Roles on the HealthCare Team: A Focus on Pharmacy
November 2011 University of Kentucky Interprofessional Education and Health
Care Seminar Series
Use of Fenoldopam in Calcineurin Inhibitor Induced Nephrotoxicity
August 2011 University of Kentucky College of Pharmacy Grand Rounds
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Effect of Etomidate on Adrenocortical Suppression:
August 2011
A Review of Intubated Septic Patients
University of Kentucky College of Pharmacy Grand Rounds
Journal Reviews
12/09- Present Annals of Pharmacotherapy
Critical Care Medicine
American Journal of Health Systems Pharmacists
Hospital Pharmacy
Journal of Pharmacy Technology
Abstract Reviews
8/2017- Present Society of Critical Care Medicine
10/2019- Present American College of Clinical Pharmacy
Grant Reviews
2018- Present Society of Critical Care Medicine DISCOVERY and Weil Grants
2018- Present American College of Clinical Pharmacy Critical Care PRN Grants
2017 TL1 University of Kentucky Pre-Doctoral Training Program
Book Chapter Reviews
07/17- Present ACCP Critical Care Pharmacy Preparatory Review and
Recertification Course
09/09
ASHP Pharm-Prep Reviewer for PCAT preparatory book
Media Interviews
“Medication Dosing in CRRT”
August 2020
Society of Critical Care Medicine iCritical Care Podcast
“Critical care pharmacist shares experience from pandemic frontlines”
May 2020
University of Kentucky media relations
https://ukhealthcare.uky.edu/wellness-community/blog/critical-care-pharmacist-sharesexperience-pandemic-frontlines
“Model placing pharmacy techs in MICU solved medication issues, boosted morale”
Sept 2017
AphA PharmacyToday
https://www.pharmacytoday.org/article/S1042-0991(17)31346-4/fulltext

ORGANIZATION MEMBERSHIP
05/18- Present NIH PETAL Network: Southeastern Clinical Center Site Coinvestigator
01/16-01/17
Critical Care Trials Network, (CCPTN) Site Investigator
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02/11- Present Society of Critical Care Medicine (SCCM):
SCCM Discovery Network Steering Committee (2018-2021)
SCCM Discovery Network collaborator (01/17- Present)
Section of Clinical Pharmacy Practice (CPP):
Research committee member Charge-1 lead (2017- present)
Programming committee member (2017- present)
Communications committee member (2012- 2013)
08/09- Present American College of Clinical Pharmacy, Member (ACCP): Critical
Care and Practice & Research Network
ACCP Certification Affairs Committee (2019-2020) Charge:
Develop mechanisms to identify ACCP member-experts who could
be recommended by the College to serve on interprofessional
guideline/consensus panels.
ACCP Public and Professional Relations Committee (2017- 2018)
Charge: Provide a recommendation to the Board of Regents on
methods to increase the number of ACCP members actively
engaged in the work of NIH study sections, national guideline
panels, and similar interprofessional work groups.
ACCP Publications Committee (2016- 2017) Charge: Develop a
white paper summarizing the future roles of pharmacy technicians
ACCP Critical Care PRN: Research Committee member:
Research Committee Chair elect (2019- Present)
Resident grant charge lead (2018- 2019)
08/06- Present American Society of Health Systems Pharmacists, Member (ASHP)
02/08- Present Phi Lambda Sigma, Beta Chi Chapter, Member (PLS)
01/08- Present Kappa Epsilon Professional Pharmacy Fraternity, Member (KE)
08/06- 08/10
American Pharmacists Association, Member (APhA)
03/09- 05/10
MUSC Presidential Scholar
05/08- 12/08
Health Speakers Toastmaster: Member
08/08- 05/10
Student Public Health Interest Group Member
04/07- 05/10
MUSC Student Government Association, Member (SGA)
Residency Leadership
06/11- 07/12
Residency Executive Committee, UK HealthCare: Chair
06/11- 07/12
Resident Advisory Committee, UK HealthCare: Member
06/11- 07/12
UK College of Pharmacy Curricular Reform: Committee member
06/10- 07/11
UK Residency Class Social Planning: Committee member
06/10- 07/11
UK Residency Class Recruitment: Committee member
06/10- 07/11
UK Chandler Hospital House Staff Council Pharmacy: Resident
Representative
06/10- 07/11
UK Pharmacy Education Advisory Committee: Resident
Representative
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HONORS AND AWARDS
10/20
12/19
08/19
06/17
02/17
01/17
07/15
01/14
06/12
04/11
05/10
05/10
04/10
03/10
05/09
10/09
10/09
10/09
2009-10
04/09
02/09
12/08
2008-09
11/08
11/08
01/08
03/07
the
08/06

Kentucky Society of Health-system Pharmacists Innovative HealthSystem Pharmacy Practice Award
SCCM CPP Innovations in Patient and Medication Safety Award
CHEST Foundation Diversity Travel Grant winner
UK HealthCare Quality and Safety Award
UK Women’s Forum Employee Educational Assistance Award
Society of Critical Care Medicine Star Research Star Achievement
Award
UK HealthCare Robert Rapp Pharmacist of the Year Award: Nominee
Society of Critical Care Medicine Research Citation Finalist Award
Outstanding Pharmacy Resident Award, UK HealthCare
Served as Chief Pharmacy Resident, UK HealthCare
Eli Lily and Company Award, MUSC-SCCP
Dean’s List member 2007-10, MUSC-SCCP
Inducted into the MUSC Student Leadership Society
South Carolina Society of Health System Pharmacy Scholarship
Inducted as a MUSC Presidential Scholar
MUSC ASHP Clinical Skills Competition: First place winner
and national competition participant
MUSC ASP Patient Counseling Competition: Top 10 finalist
“Who’s Who Among Students in American Universities and Colleges”
Phi Lambda Sigma, Chapter of the Year 2008-09
Phi Lambda Sigma, Beta Chi Chapter Member of the Year 2008-09
“Who’s Who Among Students in American Universities and Colleges”
MUSC ASHP Clinical Skills Competition: Third place winner
MUSC ASP Patient Counseling Competition: Top 10 finalist
NCBI Diversity Workshop for Student Leaders: invited participant
Cambridge Who’s Who Among Executive and Professional Women in
Pharmaceutical Industry “Honors
Edition” 2007- 10
National Scholars Honor Society Member 2006-10

VOLUNTEER ACTIVITIES
07/10- present Lexington, KY:
UK COP Salvation Army clinic, pharmacist volunteer
Leader of a Youth Mission Trip to Bowery Mission, Eastland Church
Created the Outreach Committee within the UK Residency class which coordinated
outreach and volunteer activities of the residents and UK pharmacists with the
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community. Including volunteers to the UK Children’s Hospital, Christmas letters to
soldiers abroad, and local charities
08/06- 05/10 Charleston SC:
Health Exposition in rural Spanish speaking communities
Educated families during Poison Prevention month
Phi Delta Chi clothing drive
American Cancer Society Hope Lodge
CARES free medical clinic
Crisis Ministries free medical clinic
Holiday Lighting in the horseshoe- visitor to the Children’s Hospital
Carolina Youth Development Center- Christmas Crawl
Trot for the Cure, canine cancer research event
“Shop for the Cure” Susan G. Komen fundraiser
Baskets for Breast Cancer- Hollings Cancer Center
Colleges of Charleston Relay for Life
Northwoods Clinic painted the medical clinic
American Red Cross blood drive volunteer

RESEARCH SUPPORT (ongoing)
ASHP Foundation: Pharmacy Resident Practice Advancement Grant ($5,000)
Barlow (Co-I)
01/20- /1-21
Funded
“Pharmacist-driven Fluid Stewardship in the Neurointensive Care Unit”
Role: Co-Investigator and resident advisor
ASHP Foundation: Practice Advancement Initiative Grant ($75,000)
Thompson Bastin (PI)
06/18- 06/20
Funded
Implementing a personalized medicine dosing protocol for beta-lactam antibiotics in
critically ill patients with sepsis: a prospective observational sequential period pilot study
Role: Principle Investigator

RESEARCH SUPPORT (completed)
ASHP Foundation: New Investigator Research Grant ($20,000)
Bissell (PI)
05/18- 05/20
Funded
Implementation and Evaluation of Pharmacist-Managed Diuresis in the Intensive Care
Unit
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This practice-based study will assess a pharmacist-managed diuresis protocol in a
medical ICU (MICU) on ventilator days, and ICU length of stay in patients with
recovering shock.
Role: Co-Investigator
Faculty Resources Grant, University of Kentucky ($12,000)
Flannery (PI)
06/16- 06/20
Funded
Effect of Albumin Administration of Vasopressor Duration in Resolving Septic Shock
The goal of this study is to assess the effects of albumin on vasopressor duration in septic
shock recovering from their illness.
Role: Co-Investigator
NIH/NHLBI: 1U01HL123027-01
Morris (UK Site PI)
07/14-04/20
Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute Lung
Injury (PETAL) Clinical Trials Network (U01)
University of Kentucky is a sub-site to this network. The goal of this project is to
promote health by prevention and treatment of acute lung injury through PETAL
network participation and innovative protocols. Ongoing trials (ASTER). Completed
trials (ROSE, VIOLET, CLOVERS).
Role: Site Co-Investigator (University of Kentucky)
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